

US006806060B2

(12) United States Patent

Montenegro-Chamorro et al.

(10) Patent No.: US 6,806,060 B2

(45) **Date of Patent:** Oct. 19, 2004

(54) METHODS FOR THE IDENTIFICATION OF INHIBITORS OF THREONINE SYNTHASE AS ANTIBIOTICS

(75) Inventors: Maria Victoria

Montenegro-Chamorro, Morrisville, NC (US); Sheryl Frank, Durham, NC (US); Blaise Darveaux, Hillsborough, NC (US); Sanjoy Mahanty, Chapel Hill, NC (US); Ryan Heiniger, Raleigh, NC (US); Amy Skalchunes, Raleigh, NC (US); Huaqin Pan, Apex, NC (US); Rex Tarpey, Apex, NC (US); Jeffrey Shuster, Chapel Hill, NC (US); Matthew M. Tanzer, Durham, NC (US); Lisbeth Hamer, Durham, NC (US); Kiichi Adachi, Durham, NC (US); Todd DeZwaan, Apex, NC (US); Sze-Chung Lo, Durham, NC (US)

(73) Assignee: **Icoria, Inc.**, Research Triangle Park,

NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 27 days.

(21) Appl. No.: **10/011,106**

(22) Filed: Dec. 7, 2001

(65) Prior Publication Data

US 2003/0108979 A1 Jun. 12, 2003

(51)	Int. Cl. ⁷	 C12Q 1/18; C12Q 1/02;
		C12Q 1/37; C12Q 1/00
(52)	U.S. Cl.	 435/32 ; 435/29; 435/24;
		435/23; 435/4

(56) References Cited

U.S. PATENT DOCUMENTS

4,920,109 A 4/1990 Onishi et al. 514/171

4,920,111 A	4/1990	Onishi et al 514/171
4,920,112 A	4/1990	Onishi et al 514/171
4,920,113 A	4/1990	Onishi et al 514/171
4,921,844 A	5/1990	Onishi et al 514/171
5,698,425 A	* 12/1997	Ligon et al 435/172.3
5,976,848 A	11/1999	Davis et al 435/183
6,074,830 A	6/2000	Bacot et al 435/6

FOREIGN PATENT DOCUMENTS

WO WO 01/31024 A1 * 5/2001

OTHER PUBLICATIONS

Webster' Dictionary; p. 113; 1984.*

Aufauvre–Brown, Agnes et al., "Aspergillus fumigatus chsE: A Gene Related to CHS3 of Saccharomyces cerevisiae and Important for Hyphal Growth and Conidiophore Development but Not Pathogenicity." Fungal Genetics and Biology (1997) 21: 141–152.

(List continued on next page.)


Primary Examiner—Louise N. Leary (74) Attorney, Agent, or Firm—Laura L. Kiefer; Timothy G. Hofmeyer; Deborah H. Spencer

(57) ABSTRACT

The present inventors have discovered that Threonine synthase is essential for fungal pathogenicity. Specifically, the inhibition of Threonine synthase gene expression in fungi results in no signs of successful infection or lesions. Thus, Threonine synthase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit Threonine synthase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.

47 Claims, 3 Drawing Sheets

O-phospho-L-homoserine and water



L-threonine and orthophosphate

OTHER PUBLICATIONS

Tang, Chrisoph M. et al., "Virulence Studies of Aspergillus nidulans Mutants Requiring Lysine or p-Aminobenzoic Acid in Invasive Pulmonary Aspergillosis." Infection and Immunity (1994) Dec.: 5255–5260.

Brown, Jeremy S. et al., "Signature-tagged and directed mutagenesis identify PABA synthetase as essential for *Aspergillus fumigatus* pathocenicity." Molecular Microbiology (2000) 36(6): 1371–1380.

D'Enfert, Christophe., "Attenuated Virulence of Uridine–Uracil Auxtrophs of *Aspergillus fumigatus*." Infection and Immunity (1996) Oct.: 4401–4405.

Hensel, M. et al, "The role of the *Aspergillus fumigatus* are A gene in invasive pulmonary aspergillosis." Mol. Gen enet (1998): 553–557.

Shibuya, Kazutoshi et al., "Histopathology of experimental invasive pulmonary aspergillosis in rats: Pathological comparison of pulmonary lesions induced by specific virulent factor deficient mutants." Microbial Pathogenesis (1999) 27: 123–131.

Smith, Joanne M. et al., "Virulence of Aspergillus fumigatus Double Mutants Lacking Restrictocin and an Alkaline Protease in a Low-Dose Model of Invasive Pulmonary Apergillosis." Infection and Immunity (1994) Dec.: 5247–5254.

Reichard U. et al, Virulence of an aspergillopepsin-deficient mutant of *Aspergillus fumigatus* and evidence for another aspartic proteinase linked to the fungal cell wall. J Med Vet Mycol (1997) May–Jun.; 35 (3): 189–96.

Aas, Sten F. et al.; "Nucleotide sequence of the yeast THR4 gene encoding threonine synthase"; Nucleic Acids Research; 1990; vol. 18(3):p665.

Mannhaupt Gertrud et al.; "Yeast Sequencing Reports: Analysis of the THR4 Region on Chromosome III of the Yeast *Saccharomyces cerevisiae*"; Yeast; 1990, vol. 6: pp. 353–361.

Altmann–Jöhl, R. et al.; "Ag THR4, a new selection marker for transformation of the filamentous fungus *Ashbya gossypii*, maps in a four–gene cluster that is conserved between *A. gossypii* and *Saccharmyces cerevisiae*" Mol. Gen. Genet; 1996; vol. 250: pp.: 69–80.

McCusker, J.H. et al.; "Mutation in *Saccharaomyces cerevisiae* Which Confer Resistance to Several Amino Acid Analogs"; Mollecular and Cellular Biology; Jun. 1990; vol. 10(6): pp. 2941–2949.

Ramos, C. et al; "Biochemical evidence that the *Saccharomyces cerevisiae* THR4 gene encodes threonine synthetase"; FEBS Letters 351 (1994) 357–359.

Laber et al.," Mechanisms of Interaction of Escherilchia coli threonine Synthase with Substrates and Inhibitors"; Biochemistry; 1994; vol. 33; pp. 3413–3423.


Laber etal.; "Inactivation of Eschericia coli threonine Synthase by DL–Z–2–amino–5–phosphono–3–pentenoic acid"; Arch Microbiol; 1994; vol. 161; pp. 400–403.

* cited by examiner

Oct. 19, 2004

Figure 1

O-phospho-L-homoserine and water



L-threonine and orthophosphate

Figure 2






Figure 3



Oct. 19, 2004



Minimal plus L-threonine



METHODS FOR THE IDENTIFICATION OF INHIBITORS OF THREONINE SYNTHASE AS ANTIBIOTICS

FIELD OF THE INVENTION

The invention relates generally to methods for the identification of antibiotics, preferably antifungals that affect the biosynthesis of L-threonine.

BACKGROUND OF THE INVENTION

Filamentous fungi are the causal agents responsible for many serious pathogenic infections of plants and animals. Since fungi are eukaryotes, and thus more similar to their 15 host organisms than, for example bacteria, the treatment of infections by fungi poses special risks and challenges not encountered with other types of infections. One such fungus is Magnaporthe grisea, the fungus that causes rice blast disease. It is an organism that poses a significant threat to 20 food supplies worldwide. Other examples of plant pathogens of economic importance include the pathogens in the genera Agaricus, Alternaria, Anisogramma, Anthracoidea, Antrodia, Apiognomonia, Apiosporina, Armillaria, Ascochyta, Aspergillus, Bipolaris, Bjerkandera, 25 Botryosphaeria, Botrytis, Ceratobasidium, Ceratocystis, Cercospora, Cercosporidium, Cerotelium, Cerrena, Chondrostereum, Chryphonectria, Chrysomyxa, Cladosporium, Claviceps, Cochliobolus, Coleosporium, Colletotrichium, Colletotrichum, Corticium, Corvnespora, 30 Cronartium, Cryphonectria, Cryptosphaeria, Cyathus, Cymadothea, Cytospora, Daedaleopsis, Diaporthe, Didymella, Diplocarpon, Diplodia, Discohainesia, Discula, Dothistroma, Drechslera, Echinodontium, Elsinoe, Exobasidium, Exserohilum, Fomes, Fomitopsis, Fusarium, Gaeumannomyces, Ganoderma, Gibberella, Gloeocercospora, Gloeophyllum, Gloeoporus, Glomerella, Gnomoniella, Guignardia, Gymnosporangium, Helminthosporium, Herpotrichia, Heterobasidion, 40 Hirschioporus, Hypodermella, Inonotus, Irpex, Kabatiella, Kabatina, Laetiporus, Laetisaria, Lasiodiplodia, Laxitextum, Leptographium, Leptosphaeria, Leptosphaerulina, Leucytospora, Linospora, Lophodermella, Lophodermium, Macrophomina, 45 Magnaporthe, Marssonina, Melampsora, Melampsorella, Meria, Microdochium, Microsphaera, Monilinia, Monochaetia, Morchella, Mycosphaerella, Myrothecium, Nectria, Nigrdspora, Ophiosphaerella, Ophiostoma, Penicillium, Perenniporia, Peridermium, Pestalotia, 50 Phaeocryptopus, Phaeolus, Phakopsora, Phellinus, Phialophora, Phoma, Phomopsis, Phragmidium, Phyllachora, Phyllactinia, Phyllosticta, Phymatotrichopsis, Pleospora, Podosphaera, Pseudopeziza, Pseudoseptoria, Puccinia, Pucciniastrum, Pyricularia, Rhabdocline, 55 Rhizoctonia, Rhizopus, Rhizosphaera, Rhynchosporium, Rhytisma, Schizophyllum, Schizopora, Scirrhia, Sclerotinia, Sclerotium, Scytinostroma, Septoria, Setosphaera, Sirococcus, Spaerotheca, Sphaeropsis, Sphaerotheca, Sporisorium, Stagonospora, Stemphylium, Stenocarpella, 60 Stereum, Taphrina, Thielaviopsis, Tilletia, Trametes, Tranzschelia, Trichoderma, Tubakia, Typhula, Uncinula, Urocystis, Uromyces, Ustilago, Valsa, Venturia, Verticillium, Xylaria, and others. Related organisms in the classification, oomycetes, that include the genera Albugo, Aphanomyces, 65 Bremia, Peronospora, Phytophthora, Plasmodiophora, Plasmopara, Pseudoperonospora, Pythium, Sclerophthora,

2

and others are also significant plant pathogens and are sometimes classified along with the true fungi. Human diseases that are caused by filamentous fungi include lifethreatening lung and disseminated diseases, often a result of infections by Aspergillus fumigatus. Other fungal diseases in animals are caused by fungi in the genera, Fusarium, Blastomyces, Microsporum, Trichophyton, Epidermophyton, Candida, Histoplamsa, Pneumocystis, Cryptococcus, other Aspergilli, and others. The control of fungal diseases in plants and animals is usually mediated by chemicals that inhibit the growth, proliferation, and/or pathogenicity of the fungal organisms. To date, there are less than twenty known modes-of-action for plant protection fungicides and human antifungal compounds.

A pathogenic organism has been defined as an organism that causes, or is capable of causing disease. Pathogenic organisms propagate on or in tissues and may obtain nutrients and other essential materials from their hosts. A substantial amount of work concerning filamentous fungal pathogens has been performed with the human pathogen, Aspergillus fumigatus. Shibuya et al. (Shibuya, K., M. Takaoka, et al. (1999) Microb Pathog 27: 123-31 (PMID: 10455003)) have shown that the deletion of either of two suspected pathogenicity related genes encoding an alkaline protease or a hydrophobin (rodlet) respectively, did not reduce mortality of mice infected with these mutant strains. Smith et al. (Smith, J. M., C. M. Tang, et al. (1994) Infect Immun 62: 5247-54 (PMID: 7960101)) showed similar results with alkaline protease and the ribotoxin restrictocin; Aspergillus fumigatus strains mutated for either of these genes were fully pathogenic to mice. Reichard et al. (Reichard, U., M. Monod, et al. (1997) J Med Vet Mycol 35: 189-96 (PMID: 9229335)) showed that deletion of the suspected pathogenicity gene encoding aspergillopepsin (PEP) in Aspergillus fumigatus had no effect on mortality in Endocronartium, Endothia, Entyloma, Epichloe, Erysiphe, 35 a guinea pig model system, and Aufauvre-Brown et al (Aufauvre-Brown, A., E. Mellado, et al. (1997) Fungal Genet Biol 21: 141–52 (PMID: 9073488)) showed no effects of a chitin synthase mutation on pathogenicity. However, not all experiments produced negative results. Ergosterol is an important membrane component found in fungal organisms. Pathogenic fungi that lack key enzymes in this biochemical pathway might be expected to be non-pathogenic since neither the plant nor animal hosts contain this particular sterol. Many antifungal compounds that affect this biochemical pathway have been described (Onishi, J. C. and A. A. Patchett (1990a, b, c, d, and e) U.S. Pat. Nos. 4,920,109; 4,920,111; 4,920,112; 4,920,113; and 4,921,844, Merck & Co. Inc. (Rahway N.J.)) and (Hewitt, H. G. (1998) Fungicides in Crop Protection Cambridge, University Press). D'Enfert et al. (D'Enfert, C., M. Diaquin, et al. (1996) Infect Immun 64: 4401-5 (PMID: 8926121)) showed that an Aspergillus fumigatus strain mutated in an orotidine 5'-phosphate decarboxylase gene was entirely nonpathogenic in mice, and Brown et al. (Brown, J. S., A. Aufauvre-Brown, et al. (2000) Mol Microbiol 36: 1371-80 (PMID: 10931287)) observed a non-pathogenic result when genes involved in the synthesis of para-aminobenzoic acid were mutated. Some specific target genes have been described as having utility for the screening of inhibitors of plant pathogenic fungi. Bacot et al. (Bacot, K. O., D. B. Jordan, et al. (2000) U.S. Pat. No. 6,074,830, E. I. du Pont de Nemours & Company (Wilmington Del.)) describe the use of 3,4-dihydroxy-2-butanone 4-phosphate synthase, and Davis et al. (Davis, G. E., G. D. Gustafson, et al. (1999) U.S. Pat. No. 5,976,848, Dow AgroSciences LLC (Indianapolis Ind.)) describe the use of dihydroorotate dehydrogenase for potential screening purposes.

There are also a number of papers that report less clear results, showing neither full pathogenicity nor non-pathogenicity of mutants. Hensel et al. (Hensel, M., H. N. Arst, Jr., et al. (1998) Mol Gen Genet 258: 553–7 (PMID: 9669338)) showed only moderate effects of the deletion of 5 the areA transcriptional activator on the pathogenicity of Aspergillus fumigatus.

Therefore, it is not currently possible to determine which specific growth materials may be readily obtained by a pathogen from its host, and which materials may not. We 10 have found that Magnaporthe grisea that cannot synthesize their own L-threonine are non-pathogenic on their host organism. To date there do not appear to be any publications demonstrating an anti-pathogenic effect of the knock-out, over-expression, antisense expression, or inhibition of the 15 genes or gene products involved in L-threonine biosynthesis in filamentous fungi. Thus, it has not been shown that the de novo biosynthesis of L-threonine is essential for fungal pathogenicity. Thus, it would be desirable to determine the utility of the enzymes involved in L-threonine biosynthesis 20 for evaluating antibiotic compounds, especially fungicides. If a fungal biochemical pathway or specific gene product in that pathway is shown to be required for fungal pathogenicity, various formats of in vitro and in vivo screening assays may be put in place to discover classes of 25 chemical compounds that react with the validated target gene, gene product, or biochemical pathway, and are thus candidates for antifungal, biocide, and biostatic materials.

SUMMARY OF THE INVENTION

Surprisingly, the present inventors have discovered that in vivo disruption of the gene encoding Threonine synthase in *Magnaporthe grisea* prevents or inhibits the pathogenicity of the fungus. Thus, the present inventors have discovered that Threonine synthase is essential for normal rice blast pathogenicity, and can be used as a target for the identification of antibiotics, preferably fungicides. Accordingly, the present invention provides methods for the identification of compounds that inhibit Threonine synthase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably fungicides.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the reaction performed by Threonine synthase (THR4) reaction. The Substrates/Products are O-phospho-L-homoserine and water and the Products/Substrates are L-threonine and orthophosphate. The function of the Threonine synthase enzyme is the interconversion of O-phospho-L-homoserine and water to L-threonine and orthophosphate. This reaction is part of the L-threonine biosynthesis pathway.

FIG. 2 shows a digital image showing the effect of THR4 gene disruption on *Magnaporthe grisea* pathogenicity using whole plant infection assays. Rice variety CO39 was inoculated with wild-type and the transposon insertion strains, KO1-3 and KO1-22. Leaf segments were imaged at five days post-inoculation.

FIG. 3. Verification of Gene Function by Analysis of Nutritional Requirements. Wild-type and transposon insertion strains, KO1-3 and KO1-22, were grown in (A) minimal media and (B) minimal media with the addition of L-threonine, respectively. The x-axis shows time in days and the y-axis shows turbidity measured at 490 nanometers and 750 nanometers. The symbols represent wildtype (--♠--), 65 transposon strain KO1-3 (--■--), and transposon strain KO1-22 (--♠--).

4

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise indicated, the following terms are intended to have the following meanings in interpreting the present invention.

The term "active against" in the context of compounds, agents, or compositions having antibiotic activity indicates that the compound exerts an effect on a particular target or targets which is deleterious to the in vitro and/or in vivo growth of an organism having that target or targets. In particular, a compound active against a gene exerts an action on a target which affects an expression product of that gene. This does not necessarily mean that the compound acts directly on the expression product of the gene, but instead indicates that the compound affects the expression product in a deleterious manner. Thus, the direct target of the compound may be, for example, at an upstream component which reduces transcription from the gene, resulting in a lower level of expression. Likewise, the compound may affect the level of translation of a polypeptide expression product, or may act on a downstream component of a biochemical pathway in which the expression product of the gene has a major biological role. Consequently, such a compound can be said to be active against the gene, against the gene product, or against the related component either upstream or downstream of that gene or expression product. While the term "active against" encompasses a broad range of potential activities, it also implies some degree of specificity of target. Therefore, for example, a general protease is not "active against" a particular gene which produces a polypeptide product. In contrast, a compound which inhibits a particular enzyme is active against that enzyme and against the gene which codes for that enzyme.

As used herein, the term "allele" refers to any of the alternative forms of a gene that may occur at a given locus.

The term "antibiotic" refers to any substance or compound that when contacted with a living cell, organism, virus, or other entity capable of replication, results in a reduction of growth, viability, or pathogenicity of that entity.

The term "binding" refers to a non-covalent or a covalent interaction, preferably non-covalent, that holds two molecules together. For example, two such molecules could be an enzyme and an inhibitor of that enzyme. Non-covalent interactions include hydrogen bonding, ionic interactions among charged groups, van der Waals interactions and hydrophobic interactions among nonpolar groups. One or more of these interactions can mediate the binding of two molecules to each other.

The term "biochemical pathway" or "pathway" refers to a connected series of biochemical reactions normally occurring in a cell, or more broadly a cellular event such as cellular division or DNA replication. Typically, the steps in such a biochemical pathway act in a coordinated fashion to produce a specific product or products or to produce some other particular biochemical action. Such a biochemical pathway requires the expression product of a gene if the absence of that expression product either directly or indirectly prevents the completion of one or more steps in that pathway, thereby preventing or significantly reducing the production of one or more normal products or effects of that pathway. Thus, an agent specifically inhibits such a biochemical pathway requiring the expression product of a particular gene if the presence of the agent stops or substantially reduces the completion of the series of steps in that pathway. Such an agent, may, but does not necessarily, act directly on the expression product of that particular gene.

As used herein, the term "cDNA" means complementary deoxyribonucleic acid.

As used herein, the term "CoA" means coenzyme A.

As used herein, the term "conditional lethal" refers to a mutation permitting growth and/or survival only under special growth or environmental conditions.

As used herein, the term "cosmid" refers to a hybrid vector, used in gene cloning, that includes a cos site (from the lambda bacteriophage). It also contains drug resistance marker genes and other plasmid genes. Cosmids are especially suitable for cloning large genes or multigene fragments

As used herein, the term "dominant allele" refers to a dominant mutant allele in which a discernable mutant phenotype can be detected when this mutation is present in an organism that also contains a wild type (non-mutant), recessive allele, or other dominant allele.

As used herein, the term "DNA" means deoxyribonucleic

As used herein, the term "ELISA" means enzyme-linked immunosorbent assay.

"Fungi" (singular: fungus) refers to whole fungi, fungal organs and tissues (e.g., asci, hyphae, pseudohyphae, rhizoid, scierotia, sterigmata, spores, sporodochia, 25 sporangia, synnemata, conidia, ascostroma, cleistothecia, mycelia, perithecia, basidia and the like), spores, fungal cells and the progeny thereof. Fungi are a group of organisms (about 50,000 known species), including, but not limited to, mushrooms, mildews, moulds, yeasts, etc., comprising the 30 kingdom Fungi. They can either exist as single cells or make up a multicellular body called a mycelium, which consists of filaments known as hyphae. Most fungal cells are multinucleate and have cell walls, composed chiefly of chitin. Fungi exist primarily in damp situations on land and, 35 because of the absence of chlorophyll and thus the inability to manufacture their own food by photosynthesis, are either parasites on other organisms or saprotrophs feeding on dead organic matter. The principal criteria used in classification are the nature of the spores produced and the presence or 40 absence of cross walls within the hyphae. Fungi are distributed worldwide in terrestrial, freshwater, and marine habitats. Some live in the soil. Many pathogenic fungi cause disease in animals and man or in plants, while some saprotrophs are destructive to timber, textiles, and other materials. 45 Some fungi form associations with other organisms, most notably with algae to form lichens.

As used herein, the term "fungicide", "antifungal", or "antimycotic" refers to an antibiotic substance or compound that kills or suppresses the growth, viability, or pathogenicity of at least one fungus, fungal cell, fungal tissue or spore.

In the context of this disclosure, "gene" should be understood to refer to a unit of heredity. Each gene is composed of a linear chain of deoxyribonucleotides which can be referred to by the sequence of nucleotides forming the chain. 55 Thus, "sequence" is used to indicate both the ordered listing of the nucleotides which form the chain, and the chain, itself, which has that sequence of nucleotides. ("Sequence" is used in the similar way in referring to RNA chains, linear chains made of ribonucleotides). The gene may include regulatory 60 and control sequences, sequences which can be transcribed into an RNA molecule, and may contain sequences with unknown function. The majority of the RNA transcription products are messenger RNAs (mRNAs), which include sequences which are translated into polypeptides and may 65 include sequences which are not translated. It should be recognized that small differences in nucleotide sequence for

6

the same gene can exist between different fungal strains, or even within a particular fungal strain, without altering the identity of the gene.

As used in this disclosure, the terms "growth" or "cell growth" of an organism refers to an increase in mass, density, or number of cells of said organism. Some common methods for the measurement of growth include the determination of the optical density of a cell suspension, the counting of the number of cells in a fixed volume, the counting of the number of cells by measurement of cell division, the measurement of cellular mass or cellular volume, and the like.

As used in this disclosure, the term "growth conditional phenotype" indicates that a fungal strain having such a phenotype exhibits a significantly greater difference in growth rates in response to a change in one or more of the culture parameters than an otherwise similar strain not having a growth conditional phenotype. Typically, a growth conditional phenotype is described with respect to a single growth culture parameter, such as temperature. Thus, a temperature (or heat-sensitive) mutant (i.e., a fungal strain having a heat-sensitive phenotype) exhibits significantly different growth, and preferably no growth, under nonpermissive temperature conditions as compared to growth under permissive conditions. In addition, such mutants preferably also show intermediate growth rates at intermediate, or semi-permissive, temperatures. Similar responses also result from the appropriate growth changes for other types of growth conditional phenotypes.

As used herein, the term "H₂O" means water.

As used herein, the term "heterologous THR4 gene" means a gene, not derived from *Magnaporthe grisea*, and having: at least 50% sequence identity, preferably 60%, 70%, 80%, 90%, 95%, 99% sequence identity and each integer unit of sequence identity from 50–100% in ascending order to SEQ ID NO: 1 or SEQ ID NO: 2; or at least 10% of the activity of a *Magnaporthe grisea* Threonine synthase, preferably 25%, 50%, 75%, 90%, 95%, 99% and each integer unit of activity from 10–100% in ascending order.

As used herein, the term "His-Tag" refers to an encoded polypeptide consisting of multiple consecutive histidine amino acids.

As used herein, the term "HPLC" means high pressure liquid chromatography.

As used herein, the terms "hph", "hygromycin B phosphotransferase", and "hygromycin resistance gene" refer to the *E. coli* hygromycin phosphotransferase gene or gene product.

As used herein, the term "hygromycin B" refers to an aminoglycosidic antibiotic, used for selection and maintenance of eukaryotic cells containing the *E. coli* hygromycin resistance gene.

"Hypersensitive" refers to a phenotype in which cells are more sensitive to antibiotic compounds than are wild-type cells of similar or identical genetic background.

"Hyposensitive" refers to a phenotype in which cells are less sensitive to antibiotic compounds than are wild-type cells of similar or identical genetic background.

As used herein, the term "imperfect state" refers to a classification of a fungal organism having no demonstrable sexual life stage.

The term "inhibitor", as used herein, refers to a chemical substance that inactivates the enzymatic activity of Threonine synthase or substantially reduces the level of enzymatic activity, wherein "substantially" means a reduction at least

as great as the standard deviation for a measurement, preferably a reduction by 50%, more preferably a reduction of at least one magnitude, i.e. to 10%. The inhibitor may function by interacting directly with the enzyme, a cofactor of the enzyme, the substrate of the enzyme, or any combination thereof.

A polynucleotide may be "introduced" into a fungal cell by any means known to those of skill in the art, including transfection, transformation or transduction, transposable element, electroporation, particle bombardment, infection and the like. The introduced polynucleotide may be maintained in the cell stably if it is incorporated into a non-chromosomal autonomous replicon or integrated into the fungal chromosome. Alternatively, the introduced polynucleotide may be present on an extra-chromosomal non-replicating vector and be transiently expressed or transiently

As used herein, the term "knockout" or "gene disruption" refers to the creation of organisms carrying a null mutation (a mutation in which there is no active gene product), a partial null mutation or mutations, or an alteration or alterations in gene regulation by interrupting a DNA sequence through insertion of a foreign piece of DNA. Usually the foreign DNA encodes a selectable marker.

As used herein, the term "LB agar" means Luria's Broth agar.

The term "method of screening" means that the method is suitable, and is typically used, for testing for a particular property or effect in a large number of compounds. Typically, more than one compound is tested simultaneously (as in a 96-well microtiter plate), and preferably significant 30 portions of the procedure can be automated. "Method of screening" also refers to the determination of a set of different properties or effects of one compound simultaneously.

As used herein, the term "mRNA" means messenger $_{\rm 35}$ ribonucleic acid.

As used herein, the term "mutant form" of a gene refers to a gene which has been altered, either naturally or artificially, changing the base sequence of the gene. The change in the base sequence may be of several different 40 types, including changes of one or more bases for different bases, deletions, and/or insertions, such as by a transposon. By contrast, a normal form of a gene (wild type) is a form commonly found in natural populations of an organism. Commonly a single form of a gene will predominate in 45 natural populations. In general, such a gene is suitable as a normal form of a gene, however, other forms which provide similar functional characteristics may also be used as a normal gene. In particular, a normal form of a gene does not confer a growth conditional phenotype on the strain having 50 that gene, while a mutant form of a gene suitable for use in these methods does provide such a growth conditional phenotype.

As used herein, the term "Ni" refers to nickel.

As used herein, the term "Ni-NTA" refers to nickel 55 its either hypersensitivity or hyposensitivity. Sepharose. The term "specific binding" refers to

As used herein, a "normal" form of a gene (wild type) is a form commonly found in natural populations of an organism. Commonly a single form of a gene will predominate in natural populations. In general, such a gene is suitable as a 60 normal form of a gene, however, other forms which provide similar functional characteristics may also be used as a normal gene. In particular, a normal form of a gene does not confer a growth conditional phenotype on the strain having that gene, while a mutant form of a gene suitable for use in 65 these methods does provide such a growth conditional phenotype.

8

As used herein, the term "one form" of a gene is synonymous with the term "gene", and a "different form" of a gene refers to a gene that has greater than 49% sequence identity and less than 100% sequence identity with said first form.

As used herein, the term "pathogenicity" refers to a capability of causing disease. The term is applied to parasitic microorganisms in relation to their hosts.

As used herein, the term "PCR" means polymerase chain reaction.

The "percent (%) sequence identity" between two polynucleotide or two polypeptide sequences is determined according to the either the BLAST program (Basic Local Alignment Search Tool; (Altschul, S. F., W. Gish, et al. (1990) J Mol Biol 215: 403–10 (PMID: 2231712)) at the National Center for Biotechnology or using Smith Waterman Alignment (Smith, T. F. and M. S. Waterman (1981) J Mol Biol 147: 195–7 (PMID: 7265238)) as incorporated into GeneMatcher Plus™. It is understood that for the purposes of determining sequence identity when comparing a DNA sequence to an RNA sequence, a thymine nucleotide is equivalent to a uracil nucleotide.

By "polypeptide" is meant a chain of at least two amino acids joined by peptide bonds. The chain may be linear, branched, circular or combinations thereof. Preferably, polypeptides are from about 10 to about 1000 amino acids in length, more preferably 10–50 amino acids in length. The polypeptides may contain amino acid analogs and other modifications, including, but not limited to glycosylated or phosphorylated residues.

As used herein, the term "proliferation" is synonymous to the term "growth".

As used herein, the term "reverse transcriptase-PCR" means reverse transcription-polymerase chain reaction.

As used herein, the term "RNA" means ribonucleic acid. As used herein, "semi-permissive conditions" are conditions in which the relevant culture parameter for a particular growth conditional phenotype is intermediate between permissive conditions and non-permissive conditions. Consequently, in semi-permissive conditions an organism having a growth conditional phenotype will exhibit growth rates intermediate between those shown in permissive conditions and non-permissive conditions. In general, such intermediate growth rate may be due to a mutant cellular component which is partially functional under semipermissive conditions, essentially fully functional under permissive conditions, and is non-functional or has very low function under non-permissive conditions, where the level of function of that component is related to the growth rate of the organism. An intermediate growth rate may also be a result of a nutrient substance or substances that are present in amounts not sufficient for optimal growth rates to be achieved.

"Sensitivity phenotype" refers to a phenotype that exhibits either hypersensitivity or hyposensitivity.

The term "specific binding" refers to an interaction between Threonine synthase and a molecule or compound, wherein the interaction is dependent upon the primary amino acid sequence and/or the conformation of Threonine synthase.

As used herein, the term "THR4" means a gene encoding Threonine synthase activity, referring to an enzyme that catalyses the interconversion of O-phospho-L-homoserine and water with L-threonine and orthophosphate, and may also be used to refer to the gene product.

As used herein, the terms "Threonine synthase" (EC 4.2.99.2) and "Threonine synthase polypeptide" are synony-

(

mous with "the THR4 gene product" and refer to an enzyme that catalyses the interconversion of O-phospho-L-homoserine and water with L-threonine and orthophosphate.

As used herein, the term "TLC" means thin layer chromatography.

"Transform", as used herein, refers to the introduction of a polynucleotide (single or double stranded DNA, RNA, or a combination thereof) into a living cell by any means. Transformation may be accomplished by a variety of methods, including, but not limited to, electroporation, polyethylene glycol mediated uptake, particle bombardment, agrotransformation, and the like. This process may result in transient or stable expression of the transformed polynucleotide. By "stably transformed" is meant that the sequence of interest is integrated into a replicon in the cell, such as a chromosome or episome. Transformed cells encompass not only the end product of a transformation process, but also the progeny thereof which retain the polynucleotide of interest.

For the purposes of the invention, "transgenic" refers to any cell, spore, tissue or part, that contains all or part of at least one recombinant polynucleotide. In many cases, all or part of the recombinant polynucleotide is stably integrated into a chromosome or stable extra-chromosomal element, so that it is passed on to successive generations.

As used herein, the term "transposase" refers to an enzyme that catalyzes transposition. Preferred transposons are described in WO 00/55346, PCT/US00/07317, and U.S. Ser. No. 09/658,859.

As used herein, the term "transposition" refers to a complex genetic rearrangement process involving the movement or copying of a polynucleotide (transposon) from one location and insertion into another, often within or between a genome or genomes, or DNA constructs such as plasmids, 35 bacmids, and cosmids.

As used herein, the term "transposon" (also known as a "transposable element", "transposable genetic element", "mobile element", or "jumping gene") refers to a mobile DNA element such as those, for example, described in WO 40 00/55346, PCT/US00/07317, and U.S. Ser. No. 09/658,859. Transposons can disrupt gene expression or cause deletions and inversions, and hence affect both the genotype and phenotype of the organisms concerned. The mobility of transposable elements has long been used in genetic 45 manipulation, to introduce genes or other information into the genome of certain model systems.

As used herein, the term "Tween 20" means sorbitan mono-9-octadecenoate poly(oxy-1,1-ethanediyl).

As used in this disclosure, the term "viability" of an organism refers to the ability of an organism to demonstrate growth under conditions appropriate for said organism, or to demonstrate an active cellular function. Some examples of active cellular functions include respiration as measured by gas evolution, secretion of proteins and/or other compounds, dye exclusion, mobility, dye oxidation, dye reduction, pigment production, changes in medium acidity, and the like.

The present inventors have discovered that disruption of the THR4 gene and/or gene product inhibits the pathogenicity of *Magnaporthe grisea*. Thus, the inventors are the first to demonstrate that Threonine synthase is a target for antibiotics, preferably antifungals.

Accordingly, the invention provides methods for identifying compounds that inhibit THR4 gene expression or 65 biological activity of its gene product(s). Such methods include ligand binding assays, assays for enzyme activity,

10

cell-based assays, and assays for THR4 gene expression. Any compound that is a ligand for Threonine synthase may have antibiotic activity. For the purposes of the invention, "ligand" refers to a molecule that will bind to a site on a polypeptide. The compounds identified by the methods of the invention are useful as antibiotics.

Thus, in one embodiment, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

- a) contacting a Threonine synthase polypeptide with a test compound; and
- b) detecting the presence or absence of binding between said test compound and said Threonine synthase polypeptide, wherein binding indicates that said test compound is a candidate for an antibiotic.

The Threonine synthase protein may have the amino acid sequence of a naturally occurring Threonine synthase found in a fungus, animal, plant, or microorganism, or may have an amino acid sequence derived from a naturally occurring sequence. Preferably the Threonine synthase is a fungal Threonine synthase. The cDNA (SEQ ID NO: 1) encoding the Threonine synthase protein, the genomic DNA (SEQ ID NO: 2) encoding the *M. grisea* protein, and the polypeptide (SEQ ID NO: 3) can be found herein.

In one aspect, the invention also provides for a polypeptide consisting essentially of SEQ ID NO: 3. For the purposes of the invention, a polypeptide consisting essentially of SEQ ID NO: 3 has at least 80% sequence identity with SEQ ID NO: 3 and catalyses the interconversion of O-phospho-L-homoserine and water with L-threonine and orthophosphate with at least 10% of the activity of SEQ ID NO: 3. Preferably, the polypeptide consisting essentially of SEQ ID NO: 3 has at least 85% sequence identity with SEQ ID NO: 3, more preferably the sequence identity is at least 90%, most preferably the sequence identity is at least 95% or 97 or 99%, or any integer from 80-100% sequence identity in ascending order. And, preferably, the polypeptide consisting essentially of SEQ ID NO: 3 has at least 25%, at least 50%, at least 75% or at least 90% of the activity of M. grisea Threonine synthase, or any integer from 60-100% activity in ascending order.

By "fungal Threonine synthase" is meant an enzyme that can be found in at least one fungus, and which catalyzes the interconversion of O-phospho-L-homoserine and water with L-threonine and orthophosphate. The Threonine synthase may be from any of the fungi, including ascomycota, zygomycota, basidiomycota, chytridiomycota, and lichens.

In one embodiment, the Threonine synthase is a Magnaporthe Threonine synthase. Magnaporthe species include, but are not limited to, Magnaporthe rhizophila, Magnaporthe salvinii, Magnaporthe grisea and Magnaporthe poae and the imperfect states of Magnaporthe in the genus Pyricularia. Preferably, the Magnaporthe Threonine synthase is from Magnaporthe grisea.

In various embodiments, the Threonine synthase can be from Powdery Scab (Spongospora subterranea), Grey Mould (Botrytis cinerea), White Rot (Armillaria mellea), Heartrot Fungus (Ganoderma adspersum), Brown-Rot (Piptoporus betulinus), Corn Smut (Ustilago maydis), Heartrot (Polyporus squamosus), Gray Leaf Spot (Cercospora zeae-maydis), Honey Fungus (Armillaria gallica), Root rot (Armillaria luteobubalina), Shoestring Rot (Armillaria ostoyae), Banana Anthracnose Fungus (Colletotrichum musae), Apple-rotting Fungus (Monilinia fructigena), Apple-rotting Fungus (Penicillium expansum), Clubroot Disease (Plasmodiophora brassicae), Potato Blight (Phytophthora infestans), Root pathogen

(Heterobasidion annosum), Take-all Fungus (Gaeumannomyces graminis), Dutch Elm Disease (Ophiostoma ulmi), Bean Rust (Uromyces appendiculatus), Northern Leaf Spot (Cochliobolus carbonum), Milo Disease (Periconia circinata), Southern Corn Blight (Cochliobolus heterostrophus), Leaf Spot (Cochliobolus lunata), Brown Stripe (Cochliobolus stenospilus), Panama disease (Fusarium oxysporum), Wheat Head Scab Fungus (Fusarium graminearum), Cereal Foot Rot (Fusarium culmorum), Potato Black Scurf (Rhizoctonia solani), Wheat Black Stem Rust (Puccinia graminis), White mold (Sclerotinia sclerotiorum), and the like.

Fragments of a Threonine synthase polypeptide may be used in the methods of the invention, preferably if the fragments include an intact or nearly intact epitope that occurs on the biologically active wildtype Threonine synthase. The fragments comprise at least 10 consecutive amino acids of a Threonine synthase. Preferably, the fragment comprises at least 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 20, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, or at least 540 consecutive amino acids residues of a Threonine synthase. In one embodiment, the fragment is from a Magnaporthe 25 Threonine synthase. Preferably, the fragment contains an amino acid sequence conserved among fungal Threonine synthases.

Polypeptides having at least 50% sequence identity with a fungal Threonine synthase are also useful in the methods of the invention. Preferably, the sequence identity is at least 60%, more preferably the sequence identity is at least 70%, most preferably the sequence identity is at least 80% or 90 or 95 or 99%, or any integer from 60–100% sequence identity in ascending order.

In addition, it is preferred that the polypeptide has at least 10% of the activity of a fungal Threonine synthase. More preferably, the polypeptide has at least 25%, at least 50%, at least 75% or at least 90% of the activity of a fungal Threonine synthase. Most preferably, the polypeptide has at least 10%, at least 25%, at least 50%, at least 75% or at least 90% of the activity of the *M. grisea* Threonine synthase protein.

Thus, in another embodiment, the invention provides a method for identifying a test compound as a candidate for a 45 fungicide, comprising:

- a) contacting a test compound with at least one polypeptide selected from the group consisting of: a polypeptide having at least ten consecutive amino acids of a fungal Threonine synthase; a polypeptide having at 50% sequence identity with a fungal Threonine synthase; and a polypeptide having at least 10% of the activity of a fungal Threonine synthase; and
- b) detecting the presence and/or absence of binding between said test compound and said polypeptide, 55 wherein binding indicates that said test compound is a candidate for an antibiotic.

Any technique for detecting the binding of a ligand to its target may be used in the methods of the invention. For example, the ligand and target are combined in a buffer. 60 Many methods for detecting the binding of a ligand to its target are known in the art, and include, but are not limited to the detection of an immobilized ligand-target complex or the detection of a change in the properties of a target when it is bound to a ligand. For example, in one embodiment, an 65 array of immobilized candidate ligands is provided. The immobilized ligands are contacted with a Threonine syn-

thase protein or a fragment or variant thereof, the unbound protein is removed and the bound Threonine synthase is detected. In a preferred embodiment, bound Threonine synthase is detected using a labeled binding partner, such as a labeled antibody. In a variation of this assay, Threonine synthase is labeled prior to contacting the immobilized candidate ligands. Preferred labels include fluorescent or radioactive moieties. Preferred detection methods include fluorescence correlation spectroscopy (FCS) and FCS-related confocal nanofluorimetric methods.

Once a compound is identified as a candidate for an antibiotic, it can be tested for the ability to inhibit Threonine synthase enzymatic activity. The compounds can be tested using either in vitro or cell based assays. Alternatively, a compound can be tested by applying it directly to a fungus or fungal cell, or expressing it therein, and monitoring the fungus or fungal cell for changes or decreases in growth, development, viability, pathogenicity, or alterations in gene expression. Thus, in one embodiment, the invention provides a method for determining whether a compound identified as an antibiotic candidate by an above method has antifungal activity, further comprising: contacting a fungus or fungal cells with said antifungal candidate and detecting a decrease in the growth, viability, or pathogenicity of said fungus or fungal cells.

By decrease in growth, is meant that the antifungal candidate causes at least a 10% decrease in the growth of the fungus or fungal cells, as compared to the growth of the fungus or fungal cells in the absence of the antifungal candidate. By a decrease in viability is meant that at least 20% of the fungal cells, or portion of the fungus contacted with the antifungal candidate are nonviable. Preferably, the growth or viability will be decreased by at least 40%. More preferably, the growth or viability will be decreased by at least 50%, 75% or at least 90% or more. Methods for measuring fungal growth and cell viability are known to those skilled in the art. By decrease in pathogenicity, is meant that the antifungal candidate causes at least a 10% decrease in the disease caused by contact of the fungal pathogen with its host, as compared to the disease caused in the absence of the antifungal candidate. Preferably, the disease will be decreased by at least 40%. More preferably, the disease will be decreased by at least 50%, 75% or at least 90% or more. Methods for measuring fungal disease are well known to those skilled in the art, and include such metrics as lesion formation, lesion size, sporulation, respiratory failure, and/or death.

The ability of a compound to inhibit Threonine synthase activity can be detected using in vitro enzymatic assays in which the disappearance of a substrate or the appearance of a product is directly or indirectly detected. Threonine synthase catalyzes the irreversible or reversible reaction O-phospho-L-homoserine and water=L-threonine and orthophosphate (see FIG. 1). Methods for detection of O-phospho-L-homoserine, L-threonine, orthophosphate, and water, include spectrophotometry, mass spectroscopy, thin layer chromatography (TLC) and reverse phase HPLC.

Thus, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

- a)contacting O-phospho-L-homoserine and water with a Threonine synthase;
- b) contacting O-phospho-L-homoserine and water with Threonine synthase and said test compound; and
- c) determining the change in concentration for at least one
 of the following: O-phospho-L-homoserine,
 L-threonine, orthophosphate, and water, wherein a
 change in concentration for any of the above substances
 indicates that said test compound is a candidate for an
 antibiotic.

An additional method is provided by the invention for identifying a test compound as a candidate for an antibiotic, comprising:

- a) contacting L-threonine and orthophosphate with a Threonine synthase;
- b) contacting L-threonine and orthophosphate with a Threonine synthase and a test compound; and
- c) determining the change in concentration for at least one of the following: O-phospho-L-homoserine, L-threonine, orthophosphate, and water, wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

Enzymatically active fragments of a fungal Threonine synthase are also useful in the methods of the invention. For example, an enzymatically active polypeptide comprising at least 100 consecutive amino acid residues of a fungal Threonine synthase may be used in the methods of the invention. In addition, an enzymatically active polypeptide having at least 50%, 60%, 70%, 80%, 90%, 95% or at least 98% sequence identity with a fungal Threonine synthase may be used in the methods of the invention. Most preferably, the polypeptide has at least 50% sequence identity with a fungal Threonine synthase and at least 10%, 25%, 75% or at least 90% of the activity thereof.

Thus, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

- a) contacting O-phospho-L-homoserine and water with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a Threonine synthase, and a polypeptide having at least 50% sequence identity with a Threonine synthase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a Threonine synthase;
- b) contacting O-phospho-L-homoserine and water with said polypeptide and a test compound; and
- c) determining the change in concentration for at least one of the following: O-phospho-L-homoserine, 40 L-threonine, orthophosphate, and water, wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an

An additional method is provided by the invention for 45 identifying a test compound as a candidate for an antibiotic,

- a) contacting L-threonine and orthophosphate with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with 50 a Threonine synthase, and a polypeptide having at least 50% sequence identity with a Threonine synthase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a Threonine synthase;
- b) contacting L-threonine and orthophosphate, with said polypeptide and a test compound; and
- c) determining the change in concentration for at least one of the following, O-phospho-L-homoserine, L-threonine, orthophosphate, and water, wherein a 60 change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

For the in vitro enzymatic assays, Threonine synthase fungus or may be recombinantly produced in and purified from an archael, bacterial, fungal, or other eukaryotic cell

14

culture. Preferably these proteins are produced using an E. coli, yeast, or filamentous fungal expression system. Methods for the purification of Threonine synthase may be described in Malumbres et al. (1994) Appl Environ Microbiol 60: 2209-19 (PMID: 8074505). Other methods for the purification of Threonine synthase proteins and polypeptides are known to those skilled in the art.

As an alternative to in vitro assays, the invention also provides cell based assays. In one embodiment, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

- a) measuring the expression of a Threonine synthase in a cell, cells, tissue, or an organism in the absence of a test compound;
- b) contacting said cell, cells, tissue, or organism with said test compound and measuring the expression of said Threonine synthase in said cell, cells, tissue, or organism; and
- c) comparing the expression of Threonine synthase in steps (a) and (b), wherein a lower expression in the presence of said test compound indicates that said compound is a candidate for an antibiotic.

Expression of Threonine synthase can be measured by detecting the THR4 primary transcript or mRNA, Threonine 25 synthase polypeptide, or Threonine synthase enzymatic activity. Methods for detecting the expression of RNA and proteins are known to those skilled in the art. See, for example, Current Protocols in Molecular Biology Ausubel et al., eds., Greene Publishing and Wiley-Interscience, New York, 1995. The method of detection is not critical to the invention. Methods for detecting THR4 RNA include, but are not limited to amplification assays such as quantitative reverse transcriptase-PCR, and/or hybridization assays such as Northern analysis, dot blots, slot blots, in-situ hybridization, transcriptional fusions using a THR4 promoter fused to a reporter gene, DNA assays, and microarray assays.

Methods for detecting protein expression include, but are not limited to, immunodetection methods such as Western blots, ELISA assays, polyacrylamide gel electrophoresis, mass spectroscopy, and enzymatic assays. Also, any reporter gene system may be used to detect THR4 protein expression. For detection using gene reporter systems, a polynucleotide encoding a reporter protein is fused in frame with THR4, so as to produce a chimeric polypeptide. Methods for using reporter systems are known to those skilled in the art.

Chemicals, compounds or compositions identified by the above methods as modulators, preferably inhibitors, of THR4 expression or activity can then be used to control fungal growth. Diseases such as rusts, mildews, and blights spread rapidly once established. Fungicides are thus routinely applied to growing and stored crops as a preventive measure, generally as foliar sprays or seed dressings. For example, compounds that inhibit fungal growth can be applied to a fungus or expressed in a fungus, in order to prevent fungal growth. Thus, the invention provides a method for inhibiting fungal growth, comprising contacting a fungus with a compound identified by the methods of the invention as having antifungal activity.

Antifungals and antifungal inhibitor candidates identified by the methods of the invention can be used to control the growth of undesired fungi, including ascomycota, zygomycota, basidiomycota, chytridiomycota, and lichens.

Examples of undesired fungi include, but are not limited protein and derivatives thereof may be purified from a 65 to Powdery Scab (Spongospora subterranea), Grey Mould (Botrytis cinerea), White Rot (Armillaria mellea), Heartrot Fungus (Ganoderma adspersum), Brown-Rot (Piptoporus

betulinus), Corn Smut (Ustilago maydis), Heartrot (Polyporus squamosus), Gray Leaf Spot (Cercospora zeaemaydis), Honey Fungus (Armillaria gallica), Root rot (Armillaria luteobubalina), Shoestring Rot (Armillaria ostoyae), Banana Anthracnose Fungus (Colletotrichum 5 musae), Apple-rotting Fungus (Monilinia fructigena), Apple-rotting Fungus (Penicillium expansum), Clubroot Disease (Plasmodiophora brassicae), Potato Blight (Phytophthora infestans), Root pathogen (Heterobasidion Dutch Elm Disease (Ophiostoma ulmi), Bean Rust (Uromyces appendiculatus), Northern Leaf Spot (Cochliobolus carbonum), Milo Disease (Periconia circinata), Southern Corn Blight (Cochliobolus heterostrophus), Leaf Spot (Cochliobolus lunata), Brown 15 Stripe (Cochliobolus stenospilus), Panama disease (Fusarium oxysporum), Wheat Head Scab Fungus (Fusarium graminearum), Cereal Foot Rot (Fusarium culmorum), Potato Black Scurf (Rhizoctonia solani), Wheat Black Stem Rust (Puccinia graminis), White mold 20 (Sclerotinia sclerotiorum), diseases of animals such as infections of lungs, blood, brain, skin, scalp, nails or other tissues (Aspergillus fumigatus Aspergillus sp. Fusraium sp., Trichophyton sp., Epidermophyton sp., and Microsporum sp., and the like).

Also provided is a method of screening for an antibiotic by determining whether a test compound is active against the gene identified (SEQ ID NO: 1 or SEQ ID NO: 2), its gene product (SEQ ID NO: 3), or the biochemical pathway or pathways on which it functions.

In one particular embodiment, the method is performed by providing an organism having a first form of the gene corresponding to either SEQ ID NO: 1 or SEQ ID NO: 2, either a normal form, a mutant form, a homologue, or a heterologous THR4 gene that performs a similar function as 35 THR4. The first form of THR4 may or may not confer a growth conditional phenotype, i.e., a L-threonine requiring phenotype, and/or a hypersensitivity or hyposensitivity phenotype on the organism having that altered form. In one particular embodiment a mutant form contains a transposon 40 insertion. A comparison organism having a second form of a THR4, different from the first form of the gene is also provided, and the two organisms are separately contacted with a test compound. The growth of the two organisms in the presence of the test compound is then compared.

Thus, in one embodiment, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

- a) providing cells having one form of a Threonine synthase gene, and providing comparison cells having a 50 different form of a Threonine synthase gene; and
- b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and said comparison cells in the presence of the test compound, wherein a difference in growth between 55 said cells and said comparison cells in the presence of said test compound indicates that said test compound is a candidate for an antibiotic.

It is recognized in the art that the optional determination of the growth of said first organism and said comparison 60 second organism in the absence of any test compounds may be performed to control for any inherent differences in growth as a result of the different genes. It is also recognized that any combination of two different forms of a THR4 gene, including normal genes, mutant genes, homologues, and 65 functional homologues may be used in this method. Growth and/or proliferation of an organism is measured by methods

well known in the art such as optical density measurements, and the like. In a preferred embodiment the organism is Magnaporthe grisea.

Conditional lethal mutants may identify particular biochemical and/or genetic pathways given that at least one identified target gene is present in that pathway. Knowledge of these pathways allows for the screening of test compounds as candidates for antibiotics as inhibitors of the substrates, products and enzymes of the pathway. Pathways annosum), Take-all Fungus (Gaeumannomyces graminis), 10 known in the art may be found at the Kyoto Encyclopedia of Genes and Genomes and in standard biochemistry texts (Lehninger, A., D. Nelson, et al. (1993) Principles of Biochemistry, New York, Worth Publishers).

> Thus, in one embodiment, the invention provides a method for screening for test compounds acting against the biochemical and/or genetic pathway or pathways in which THR4 functions, comprising:

- a) providing cells having one form of a gene in the L-threonine biochemical and/or genetic pathway and providing comparison cells having a different form of said gene;
- b) contacting said cells and said comparison cells with a test compound; and
- c) determining the growth of said cells and said comparison cells in the presence of said test compound, wherein a difference in growth between said cells and said comparison cells in the presence of said test compound indicates that said test compound is a candidate for an antibiotic.

The use of multi-well plates for screening is a format that readily accommodates multiple different assays to characterize various compounds, concentrations of compounds, and fungal strains in varying combinations and formats. Certain testing parameters for the screening method can significantly affect the identification of growth inhibitors, and thus can be manipulated to optimize screening efficiency and/or reliability. Notable among these factors are variable sensitivities of different mutants, increasing hypersensitivity with increasingly less permissive conditions, an apparent increase in hypersensitivity with increasing compound concentration, and other factors known to those in the art.

Conditional lethal mutants may identify particular biochemical and/or genetic pathways given that at least one identified target gene is present in that pathway. Knowledge of these pathways allows for the screening of test compounds as candidates for antibiotics. Pathways known in the art may be found at the Kyoto Encyclopedia of Genes and Genomes and in standard biochemistry texts (Lehninger et al. (1993) Principles of Biochemistry).

Thus, in one embodiment, the invention provides a method for screening for test compounds acting against the biochemical and/or genetic pathway or pathways in which THR4 functions, comprising:

- (a) providing paired growth media comprising a first medium and a second medium, wherein said second medium contains a higher level of L-threonine than said first medium:
- (b) contacting an organism with a test compound;
- (c) inoculating said first and said second media with said organism; and
- (d) determining the growth of said organism, wherein a difference in growth of the organism between said first and said second media indicates that said test compound is a candidate for an antibiotic.

It is recognized in the art that determination of the growth of said organism in the paired media in the absence of any

17

test compounds may be performed to control for any inherent differences in growth as a result of the different media. Growth and/or proliferation of an organism is measured by methods well known in the art such as optical density measurements, and the like. In a preferred embodiment, the organism is *Magnaporthe grisea*.

EXPERIMENTAL

EXAMPLE 1

Construction of Plasmids with a Transposon Containing a Selectable Marker

Construction of Sif transposon

Sif was constructed using the GPS3 vector from the GPS-M mutagenesis system from New England Biolabs, Inc. (Beverly, Mass.) as a backbone. This system is based on the bacterial transposon Tn7. The following manipulations were done to GPS3 according to Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press. The kanamycin resistance gene (npt) contained between the Tn7 arms was removed by EcoRV digestion. The bacterial hygromycin B phosphotransferase (hph) gene (Gritz and Davies (1983) Gene 25: 179-88 (PMID: 6319235)) under control of the Aspergillus nidulans trpC promoter and terminator (Mullaney et al. 25 (1985) Mol Gen Genet 199: 37-45 (PMID: 3158796)) was cloned by a HpaI/EcoRV blunt ligation into the Tn7 arms of the GPS3 vector yielding pSifl. Excision of the ampicillin resistance gene (bla) from pSifl was achieved by cutting pSifl with XmnI and BglI followed by a T4 DNA polymerase treatment to remove the 3' overhangs left by the BgII digestion and religation of the plasmid to yield pSif. Top 10F' electrocompetent E. coli cells (Invitrogen) were transformed with ligation mixture according to manufacturer's recommendations. Transformants containing the Sif transposon were selected on LB agar (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual) containing 50 ug/ml of hygromycin B (Sigma Chem. Co., St. Louis, Mo.).

EXAMPLE 2

Construction of a Fungal Cosmid Library

Cosmid libraries were constructed in the pcosKA5 vector (Hamer et al. (2001) Proc Natl Acad Sci USA 98: 5110–15 (PMID: 11296265)) as described in Sambrook et al. (1989) *Molecular Cloning, a Laboratory Manual.* Cosmid libraries were quality checked by pulsed-field gel electrophoresis, restriction digestion analysis, and PCR identification of single genes.

EXAMPLE 3

Construction of Cosmids with Transposon Insertion into Fungal Genes

Sif Transposition into a Cosmid

Transposition of Sif into the cosmid framework was carried out as described by the GPS-M mutagenesis system (New England Biolabs, Inc.). Briefly, 2 ul of the 10×GPS buffer, 70 ng of supercoiled pSIF, 8–12 ug of target cosmid DNA were mixed and taken to a final volume of 20 ul with 60 water. 1 ul of transposase (TnsABC) was added to the assembly reaction and incubated for 10 minutes at 37° C. After the assembly reaction, 1 ul of start solution was added to the tube, mixed well and incubated for 1 hour at 37° C. followed by heat inactivation of the proteins at 75° C. for 10 65 min. Destruction of the remaining untransposed pSif was done by PISceI digestion at 37° C. for 2 hours followed by

18

10 min incubation at 75° C. to inactivate the proteins. Transformation of Top10F' electrocompetent cells (Invitrogen) was done according to manufacturers recommendations. Sif-containing cosmid transformants were selected by growth on LB agar plates containing 50 ug/ml of hygromycin B (Sigma Chem. Co.) and 100 ug/ml of Ampicillin (Sigma Chem. Co.).

EXAMPLE 4

High Throughput Preparation and Verification of Transposon Insertion into the *M. grisea* THR4 Gene

E. coli strains containing cosmids with transposon insertions were picked to 96 well growth blocks (Beckman Co.) containing 1.5 ml of TB (Terrific Broth, Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press) supplemented with 50 ug/ml of ampicillin. Blocks were incubated with shaking at 37° C. overnight. E. coli cells were pelleted by centrifugation and cosmids were isolated by a modified alkaline lysis method (Marra et al. (1997) Genome Res 7: 1072–84 (PMID: 9371743)). DNA quality was checked by electrophoresis on agarose gels. Cosmids were sequenced using primers from the ends of each transposon and commercial dideoxy sequencing kits (Big Dye Terminators, Perkin Elmer Co.). Sequencing reactions were analyzed on an ABI377 DNA sequencer (Perkin Elmer Co.).

DNA sequences adjacent to the site of the insertion were collected and used to search DNA and protein databases using the BLAST algorithms (Altschul et al. (1997) Nucleic Acids Res 25: 3389–3402 (PMID: 9254694)). A single insertion of SIF into the *Magnaporthe grisea* THR4 gene was chosen for further analysis. This construct was designated cpgmra0012020a04 and it contains the SIF transposon approximately between amino acids 314 and 315 relative to the *Schizosaccharomyces pombe* homologue ThrC (total length: 514 amino acids, GENBANK: 2501152).

EXAMPLE 5

Preparation of THR4 Cosmid DNA and Transformation of Magnaporthe grisea

Cosmid DNA from the THR4 transposon tagged cosmid clone was prepared using QIAGEN Plasmid Maxi Kit (QIAGEN), and digested by PI-Pspl (New England Biolabs, Inc.). Fungal electro-transformation was performed essentially as described (Wu et al. (1997) MPMI 10: 700-708). 50 Briefly, M. grisea strain Guy 11 was grown in complete liquid media (Talbot et al. (1993) Plant Cell 5: 1575-1590 (PMID: 8312740)) shaking at 120 rpm for 3 days at 25° C. in the dark. Mycelia was harvested and washed with sterile H₂O and digested with 4 mg/ml beta-glucanase (InterSpex) for 4-6 hours to generate protoplasts. Protoplasts were collected by centrifugation and resuspended in 20% sucrose at the concentration of 2×10^8 protoplasts/ml. 50 ul protoplast suspension was mixed with 10-20 ug of the cosmid DNA and pulsed using Gene Pulser II (BioRad) set with the following parameters: resistance 200 ohm, capacitance 25 uF, voltage 0.6 kV. Transformed protoplasts were regenerated in complete agar media (CM, Talbot et al. (1993) Plant Cell 5: 1575–1590 (PMID: 8312740)) with the addition of 20% sucrose for one day, then overlayed with CM agar media containing hygromycin B (250 ug/ml) to select transformants. Transformants were screened for homologous recombination events in the target gene by PCR (Hamer et

al. (2001) Proc Natl Acad Sci USA 98: 5110-15 (PMID: 11296265)). Two independent strains were identified and are hereby referred to as KO1-3 and KO1-22, respectively.

EXAMPLE 6

Effect of Transposon Insertion on Magnaporthe Pathogenicity

The target fungal strains, KO1-3 and KO1-22, obtained in Example 5 and the wild type strain, Guy11, were subjected to a pathogenicity assay to observe infection over a 1-week period. Rice infection assays were performed using Indian rice cultivar CO39 essentially as described in Valent et al. ((1991) Genetics 127: 87-101 (PMID: 2016048)). All three strains were grown for spore production on complete agar media. Spores were harvested and the concentration of spores adjusted for whole plant inoculations. Two-week-old 20 seedlings of cultivar CO39 were sprayed with 12 ml of conidial suspension (5×10⁴ conidia per ml in 0.01% Tween-20 (Polyoxyethylensorbitan monolaureate) solution). The inoculated plants were incubated in a dew chamber at 27° C. in the dark for 36 hours, and transferred to a growth chamber 25 (27° C. 12 hours/21° C. 12 hours 70% humidity) for an additional 5.5 days. Leaf samples were taken at 3, 5, and 7 days post-inoculation and examined for signs of successful infection (i.e. lesions). FIG. 2 shows the effects of THR4 30 gene disruption on Magnaporthe infection at five days post-inoculation.

EXAMPLE 7

Verification of THR4 Gene Function by Analysis of Nutritional Requirements

The fungal strains, KO1-3 and KO1-22, containing the THR4 disrupted gene obtained in Example 5 were analyzed for their nutritional requirement for L-threonine using the PM5 phenotype microarray from Biolog, Inc. (Hayward, Calif.). The PM5 plate tests for the auxotrophic requirement for 94 different metabolites. The inoculating fluid consists of 45 0.05% Phytagel, 0.03% Pluronic F68, 1% glucose, 23.5 mM NaNO₃, 6.7 mM KCl, 3.5 mM Na₂SO₄, 11 mM KH₂PO₄, 0.01% p-iodonitrotetrazolium violet, 0.1 mM MgCl₂, 1.0 mM CaCl₂ and trace elements, pH adjusted to 6.0 with NaOH. Final concentrations of trace elements are: 7.6 μ M ZnCl₂, 2.5 μM MnCl₂.4H₂O, 1.8 μM FeCl₂.4H₂O, 0.71 μM $CoCl_2.6H_2O$, 0.64 μ M $CuCl_2.2H_2O$, 0.62 μ M Na_2MoO_4 , 18 μM H₃BO₃. Spores for each strain were harvested into the inoculating fluid. The spore concentrations were adjusted to 55 2×10^5 spores/ml. 100 μ l of spore suspension were deposited into each well of the microtiter plates. The plates were incubated at 25° C. for 7 days. Optical density (OD) measurements at 490 nm and 750 nm were taken daily. The OD₄₀₀ measures the extent of tetrazolium dye reduction and the level of growth, and OD₇₅₀ measures growth only. Turbidity=OD₄₉₀+OD₇₅₀. Data confirming the annotated gene function is presented as a graph of Turbidity vs. Time showing both the mutant fungi and the wild-type control in 65 the absence (FIG. 3A) and presence (FIG. 3B) of L-threonine.

EXAMPLE 8

Cloning and Expression Strategies, Extraction and Purification of Threonine Synthase Protein

The following protocol may be employed to obtain a purified Threonine synthase protein.

Cloning and Expression Strategies

A THR4 cDNA gene can be cloned into E. coli (pET vectors-Novagen), Baculovirus (Pharmingen) and Yeast (Invitrogen) expression vectors containing His/fusion protein tags, and the expression of recombinant protein can be evaluated by SDS-PAGE and Western blot analysis. Extraction

Extract recombinant protein from 250 ml cell pellet in 3 ml of extraction buffer by sonicating 6 times, with 6 sec pulses at 4° C. Centrifuge extract at 15000×g for 10 min and collect supernatant. Assess biological activity of the recombinant protein by activity assay.

Purification

Purify recombinant protein by Ni-NTA affinity chromatography (Qiagen). Purification protocol: perform all steps at

Use 3 ml Ni-beads (Qiagen) Equilibrate column with the buffer Load protein extract Wash with the equilibration buffer Elute bound protein with 0.5 M imidazole

EXAMPLE 9

Assays for Testing Binding of Test Compounds to Threonine Synthase

The following protocol may be employed to identify test compounds that bind to the Threonine synthase protein.

Purified full-length Threonine synthase polypeptide with a His/fusion protein tag (Example 8) is bound to a HisGrab™ Nickel Coated Plate (Pierce, Rockford, Ill.). following manufacturer's instructions.

Buffer conditions are optimized (e.g. ionic strength or pH, Ramos and Calderon (1994) FEBS Lett 351: 357-9 (PMID: 8082795)) for binding of radiolabeled O-phospho-L-homoserine (Gening et al. (1994) Biokhimiia 59: 1238-44 (PMID: 7819407)) to the bound Threonine synthase.

Screening of test compounds is performed by adding test compound and radiolabeled O-phospho-L-homoserine (Gening et al. (1994) Biokhimiia 59: 1238-44 (PMID: 7819407)) to the wells of the HisGrab™ plate containing bound Threonine synthase.

The wells are washed to remove excess labeled ligand and scintillation fluid (Scintiverse®, Fisher Scientific) is added to each well.

The plates are read in a microplate scintillation counter. Candidate compounds are identified as wells with lower radioactivity as compared to control wells with no test compound added.

Additionally, a purified polypeptide comprising 10-50 amino acids from the M. grisea Threonine synthase is screened in the same way. A polypeptide comprising 10-50 amino acids is generated by subcloning a portion of the THR4 gene into a protein expression vector that adds a His-Tag when expressed (see Example 8). Oligonucleotide primers are designed to amplify a portion of the THR4 gene using the polymerase chain reaction amplification method.

20

The DNA fragment encoding a polypeptide of 10-50 amino acids is cloned into an expression vector, expressed in a host organism and purified as described in Example 8 above.

Test compounds that bind THR4 are further tested for antibiotic activity. M. grisea is grown as described for spore 5 production on oatmeal agar media (Talbot et al. (1993) Plant Cell 5: 1575-1590 (PMID: 8312740)). Spores are harvested into minimal media (Talbot et al. (1993) Plant Cell 5: 1575–1590 (PMID: 8312740)) to a concentration of 2×10^5 spores/ml and the culture is divided. The test compound is added to one culture to a final concentration of 20-100 μg/ml. Solvent only is added to the second culture. The plates are incubated at 25° C. for seven days and optical density measurements at 590 nm are taken daily. The growth curves of the solvent control sample and the test compound sample are compared. A test compound is an antibiotic 15 candidate if the growth of the culture containing the test compound is less than the growth of the control culture.

EXAMPLE 10

Assays for Testing Inhibitors or Candidates for Inhibition of Threonine Synthase Activity

The enzymatic activity of Threonine synthase is determined in the presence and absence of candidate compounds in a suitable reaction mixture, such as described by Ramos and Calderon (1994) FEBS Lett 351: 357-9 (PMID: 8082795). Candidate compounds are identified when a decrease in products or a lack of decrease in substrates is detected with the reaction proceeding in either direction.

comprising 10-50 amino acids from the M. grisea Threonine synthase is determined in the presence and absence of candidate compounds in a suitable reaction mixture, such as described by Ramos and Calderon (1994) FEBS Lett 351: amino acids is generated by subcloning a portion of the THR4 gene into a protein expression vector that adds a His-Tag when expressed (see Example 8). Oligonucleotide primers are designed to amplify a portion of the THR4 gene using polymerase chain reaction amplification method. The 40 DNA fragment encoding a polypeptide of 10-50 amino acids is cloned into an expression vector, expressed and purified as described in Example 8 above.

Test compounds identified as inhibitors of THR4 activity are further tested for antibiotic activity. Magnaporthe grisea 45 fungal cells are grown under standard fungal growth conditions that are well known and described in the art. M. grisea is grown as described for spore production on oatmeal agar media (Talbot et al. (1993) Plant Cell 5: 1575-1590 (PMID: 8312740)). Spores are harvested into 50 minimal media (Talbot et al. (1993) Plant Cell 5: 1575-1590 (PMID: 8312740)) to a concentration of 2×10⁵ spores/ml and the culture is divided. The test compound is added to one culture to a final concentration of 20–100 $\mu g/ml$. Solvent only is added to the second culture. The plates are incubated 55 at 25° C. for seven days and optical density measurements at 590 nm are taken daily. The growth curves of the solvent control sample and the test compound sample are compared. A test compound is an antibiotic candidate if the growth of the culture containing the test compound is less than the ₆₀ (PMID: 7749303)). growth of the control culture.

EXAMPLE 11

Assays for Testing Compounds for Alteration of Threonine Synthase Gene Expression

Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and 22

described in the art. Wild-type M. grisea spores are harvested from cultures grown on complete agar or oatmeal agar media after growth for 10-13 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2×10^5 spores per ml. 25 ml cultures are prepared to which test compounds will be added at various concentrations. A culture with no test compound present is included as a control. The cultures are incubated at 25° C. for 3 days after which test compound or solvent only control is added. The cultures are incubated an additional 18 hours. Fungal mycelia is harvested by filtration through Miracloth (CalBiochem®, La Jolla, Calif.), washed with water and frozen in liquid nitrogen. Total RNA is extracted with TRIZOL® Reagent using the methods provided by the manufacturer (Life Technologies, Rockville, Md.). Expression is analyzed by Northern analysis of the RNA samples as described (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press) 20 using a radiolabeled fragment of the THR4 gene as a probe. Test compounds resulting in a reduced level of THR4 mRNA relative to the untreated control sample are identified as candidate antibiotic compounds.

EXAMPLE 12

In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of Threonine Synthase with No Activity

Magnaporthe grisea fungal cells containing a mutant Additionally, the enzymatic activity of a polypeptide 30 form of the THR4 gene which abolishes enzyme activity, such as a gene containing a transposon insertion (see Examples 4 and 5), are grown under standard fungal growth conditions that are well known and described in the art. Magnaporthe grisea spores are harvested from cultures 357-9 (PMID: 8082795). A polypeptide comprising 10-50 35 grown on complete agar medium containing 4 mM L-threonine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium containing 100 µM L-threonine to a concentration of 2×10⁵ spores per ml. Approximately 4×10⁴ spores are added to each well of 96-well plates to which a test compound is added (at varying concentrations). The total volume in each well is 200 ul. Wells with no test compound present (growth control), and wells without cells are included as controls (negative control). The plates are incubated at 25° C. for seven days and optical density measurements at 590 nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound)/OD₅₉₀ (growth control)×100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the wild type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild type are identified as potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177-221

EXAMPLE 13

In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of Threonine Synthase with Reduced Activity

Magnaporthe grisea fungal cells containing a mutant form of the THR4 gene, such as a promoter truncation that

reduces expression, are grown under standard fungal growth conditions that are well known and described in the art. A promoter truncation is made by deleting a portion of the promoter upstream of the transcription start site using standard molecular biology techniques that are well known and 5 described in the art (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press). Magnaporthe grisea spores are harvested from cultures grown on complete agar medium containing 4 mM L-threonine (Sigma-Aldrich Co.) after growth for 10-13 10 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2×10^5 spores per ml. Approximately 4×10⁴ spores are added to each well of 15 96-well plates to which a test compound is added (at varying concentrations). The total volume in each well is 200 μ l. Wells with no test compound present (growth control), and wells without cells are included as controls (negative control). The plates are incubated at 25° C. for seven days 20 and optical density measurements at 590 nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the ${\rm OD}_{590}$ (fungal strain 25 plus test compound)/OD₅₉₀ (growth control)×100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the wild-type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild type are identified as 30 potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177-221).

EXAMPLE 14

In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of a Lthreonine Biosynthetic Gene with No Activity

Magnaporthe grisea fungal cells containing a mutant 40 form of a gene in the L-threonine biosynthetic pathway (e.g. Homoserine kinase (E.C. 2.7.1.39)) are grown under standard fungal growth conditions that are well known and described in the art. Magnaporthe grisea spores are harvested from cultures grown on complete agar medium 45 containing 4 mM L-threonine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium containing 100 50 μ M L-threonine to a concentration of 2×10^5 spores per ml. Approximately 4×10⁴ spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 55 200 µl. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25° C. for seven days and optical density measurements at 590 nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on 60 the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound)/OD₅₉₀ (growth control)×100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the 65 wild type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild24

type are identified as potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177–221).

EXAMPLE 15

In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of a Lthreonine Biosynthetic Gene with Reduced Activity

Magnaporthe grisea fungal cells containing a mutant form of a gene in the L-threonine biosynthetic pathway (e.g. Homoserine kinase (E.C. 2.7.1.39)), such as a promoter truncation that reduces expression, are grown under standard fungal growth conditions that are well known and described in the art. A promoter truncation is made by deleting a portion of the promoter upstream of the transcription start site using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press). Magnaporthe grisea fungal cells containing a mutant form of are grown under standard fungal growth conditions that are well known and described in the art. Magnaporthe grisea spores are harvested from cultures grown on complete agar medium containing 4 mM L-threonine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2×10^5 spores per ml. Approximately 4×10⁴ spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200 μ l. Wells with no test compound present, and wells 35 without cells are included as controls. The plates are incubated at 25° C. for seven days and optical density measurements at 590 nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound)/OD₅₉₀ (growth control)×100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the wild type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild type are identified as potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177-221).

EXAMPLE 16

In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Fungal THR4 and a Second Fungal Strain Containing a Heterologous THR4 Gene

Wild-type Magnaporthe grisea fungal cells and M. grisea fungal cells lacking a functional THR4 gene and containing a Thr4 gene from Saccharomyces cerevisiae (Genbank: 6319901, 50% sequence identity) are grown under standard fungal growth conditions that are well known and described in the art. A M. grisea strain carrying a heterologous THR4 gene is made as follows:

A *M. grisea* strain is made with a nonfunctional THR4 gene, such as one containing a transposon insertion in the native gene (see Examples 4 and 5).

A construct containing a heterologous THR4 gene is made by cloning the Thr4 gene from Saccharomyces cerevi-

siae into a fungal expression vector containing a trpC promoter and terminator (e.g. pCB1003, Carroll et al. (1994) Fungal Gen News Lett 41: 22) using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) Molecular 5 Cloning, a Laboratory Manual).

The said construct is used to transform the *M. grisea* strain lacking a functional THR4 gene (see Example 5). Transformants are selected on minimal agar medium lacking L-threonine. Only transformants carrying a ¹⁰ functional THR4 gene will grow.

Wild-type strains of Magnaporthe grisea and strains containing a heterologous form of THR4 are grown under standard fungal growth conditions that are well known and described in the art. Magnaporthe grisea spores are har- 15 vested from cultures grown on complete agar medium after growth for 10-13 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration 20 of 2×10^5 spores per ml. Approximately 4×10^4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200 µl. Wells with no test compound present, 25 and wells without cells are included as controls. The plates are incubated at 25° C. for seven days and optical density measurements at 590 nm are taken daily. The effect of each compound on the wild-type and heterologous fungal strains is measured against the growth control and the percent of 30 inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound)/OD₅₉₀ (growth control)×100. The percent of growth inhibition as a result of a test compound on the wild-type and heterologous fungal strains are compared. Compounds that show differential growth inhibition 35 between the wild-type and heterologous strains are identified as potential antifungal compounds with specificity to the native or heterologous THR4 gene products. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177-221).

26 EXAMPLE 17

Pathway Specific In Vivo Assay Screening Protocol

Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art. Wild-type M. grisea spores are harvested from cultures grown on oatmeal agar media after growth. for 10-13 days in the light at 25° C. using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium and a minimal growth medium containing 4 mM L-threonine (Sigma-Aldrich Co.) to a concentration of 2×10^5 spores per ml. The minimal growth media contains carbon, nitrogen, phosphate, and sulfate sources, and magnesium, calcium, and trace elements (for example, see inoculating fluid in Example 7). Spore suspensions are added to each well of a 96-well microtiter plate (approximately 4×10⁴ spores/well). For each well containing a spore suspension in minimal media, an additional well is present containing a spore suspension in minimal medium containing 4 mM L-threonine. Test compounds are added to wells containing spores in minimal media and minimal media containing L-threonine. The total volume in each well is 200 µl. Both minimal media and L-threonine containing media wells with no test compound are provided as controls. The plates are incubated at 25° C. for seven days and optical density measurements at 590 nm are taken daily. A compound is identified as a candidate for an antibiotic acting against the L-threonine biosynthetic pathway when the observed growth in the well containing minimal media is less than the observed growth in the well containing L-threonine as a result of the addition of the test compound. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177-221).

While the foregoing describes certain embodiments of the invention, it will be understood by those skilled in the art that variations and modifications may be made and still fall within the scope of the invention. The foregoing examples are intended to exemplify various specific embodiments of the invention and do not limit its scope in any manner.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 3 <210> SEQ ID NO 1 <211> LENGTH: 1650 <212> TYPE: DNA <213> ORGANISM: Magnaporthe grisea <400> SEQUENCE: 1 atggagaacg gtgctgcaac caacggggcg tcggagaagt cgcactctcc ttcacagacc tacctctcca caaggggaga cgattatggg ctctcattcg agaccgtcgt cctcaaaggt cttgcggctg acgggggtct tttcctgccc gaggaagtgc ccgcggcaac cgagtggcaa 180 agctggaaag acctgcccta caccgagctt gccgtcaagg ttctcagctt gtacatctcc 240 300 cccgccgagg tgccgacgga agacctcagg gcgctcgtcg agcgcagcta ctcgaccttc cgatccaagg aggttgtgcc gctggtgaag ctggaggaca accttcacct gctggagcta 360 ttccacggcc ccagctactc gttcaaggac tgcgcgctgc aattccttgg taacctcttc 420 gagtactttt tgactcgcaa gaacaaggga aaggagggca aagacaggca ccacctcact 480

eageatytt cogtottoat octgococc anggotogt taagoocca coaggagge 600 captigocoag atatogtoa gocaaatyt cacaacty cogtgacog cactitigae 660 patigocoag atatogtoa gocaagtit acquaecty cogtgacog acctitigae 720 cactogtact titotogge cactgocoag ageatty tacaagtog gocactgaag 720 cactogtact titotogge cactgocoag ageatty cacaagtog cocaagtit 600 cactogtact titotogge cactgocoag acctuage octgagacgy cacaagacgy 640 cactogtact titotogge cacggocyta cocaaagacgy tacaagatgy gocacaaga 900 cactgocoaga gocacaga gocaagacgy tacaagatga gocacaga 900 catgocoaga goggocoa acgaaagaag octgocaaga gogaagacga cocaggoggi 1020 cactgocoaga aggotogaa gotogaaagaag aggaagacci qaggocogg 1020 cacgocoaga goggocoa acgaaagaag octgocaaga gogagacci qagcocogga 1020 cacgocoaga gogactaa agaagaga gogatogga agaacacga gogaagtit 1140 potogocagagacaga gogacocogga gogatogga agaacacga agaagagata 1140 potogocagagacaga gogagacga gogatogga acacccagaa cacqagagti 1200 gocacagacaga agagacaag agagaga gogatogga acacccagaa cacqagagti 1200 gocacagacaga agagacaag agagaga gogatogga acacccagaa cacqagagti 1200 gocacagaaga agagacaag titgaaagaga gogatagga acacccagaa cacqagagati 1200 gocacaccag cacagatact togaaagac tacaagacc gocacctga gotogaggat 1200 gocacaccag cacagatact gocagagga titgatogac gogaacacg gogagagtica 1200 gocacaccag cacagatact togaagaga titgatogac agaagagag 1500 gocacaccag cacagatac gocagagaga titgatogaga gogagagaga gogagagaga 1600 gocacaccag cacagatac gocagagaga titgatogaga gogagagaga gogagagaga 1600 gocacaccag cacagagaag togagagaa titgatogaga gogagagagaga 1600 gogagactaga aggotogaaa togagagaa tittatactg gocgataga gogagagaga 1600 gogagagagaga acacggagaga tittatactg gocgataga gogagagaga 1600 gogagagagagagagagagagagagagagagagagagag	-continued	
Desgratage coggraptics commandight canameter cograncing according as contributed and selecting and according an according an according a selecting and according an according a selecting and according a selecting and according	gtggtcggcg caacaagtgg tgataccggt tcggcggcca tctatggtct tcgcaacaag	540
pattogramp atatogram gycratytic amogaccag attogaty gacactagan 720 cattgytycty tomactogat camounty of the content of the conten	aaggatgttt ccgtcttcat cctgcacccc aagggtcgtg taagccccat ccaggaggcc	600
triggigety teaactegat caarggice aggatateg eccagatity tiartactic 780 cactegitat titetetyge caggogica coagagaget teaaggiceg eqacaaagic 840 cactegitat titetetyge caggogica coagagaget teaaggiceg eqacaaagic 840 cactegitate coccacacgg gaactitggi accatatigg etgatacti tyocacaaagi 900 atgggotige cigicgaaa gitgigitgi gegacaaagi agaacgacai teitgacagg 960 bittiggaaga egggoegita egaaagaga eccepaagac ecgagagage egaaggeggi 1020 tiggecteaga atggegiaaa ggeteacgag gaggogigaa aggagacet gageceggag 1080 atgggotige geggetega egaactitgag egaacactg ggittettyc eaaggagite 1140 gedegitacag etggecteaa ggetacegga egaacactg ggittettyc eaaggagite 1120 gedegitaca agtececaaa ggetacegga ggeteegga egacegega agaactatgi 1200 gedegigaaa agaagteaa ggetacegga eggeteegga eacacccagaa ectgagatig 1220 ategegagaa tytacaaag eaaaagaga eggeteegga eacacccaga ectgagatig 1220 ategegagaa tytacaaag eaaaagaag etteegac egaactegg egitecace 1140 gedecaccaa agaagteaat gitegaggge tecaacgace egaactegg egitecaag 1140 gedecaccaa agaagteaat gitegaggge tecaacgace egaactegg egitecaag 1140 gedecaccaa eagageteti tyagaggac tecaacgace egaactegg egitecaag 1140 gedecaccaag eaaagtetic tyggegeti gagetigage teaagagaaa gaagagagite 1500 gaacatgac eaaagteeti geegaagaa titgityaga tagaagaaga gaaggagite 1500 gaacatgac gaaggagaag tagigcataa 1150 2010 SEO ID NO 2 2011 SEO ID NO 2 2012 SEO ID NO 2 2013 INNOMIN Nagaaporthe grisea 4400 SEOURNER 12 tacagetgaca accaacaga agaattgaca gaattgace gaagagaga gaagagaga 120 gaagagattga eactegacaga agaattgaca gaattgace gaagagaga gaagagaga 120 gaacatgate cactagacaga agaattgaca gaattgace tacaaaatec tycatatta 2010 SEO ID NO 2 2013 ENDOMIN NAGaaaaga tacaacatga gattgacaga gaagagaga gattgacaga 300 gaacatgactac accaacaga agaattgaca gaattgacaga tacaacagagaga gattgacaga 420 acaagagaaaa geaggaaaa getggaaaga egaagaagaa gattatagag tetaaagaga 240 cacaagagaaa cacaacaga agaagaaga egaacagaa agaagagaa 300 gaacactact teaaacaga tacaacagaa eaaagagaa gattaacagat tecaaagaa 240 cacaagagaaaa eacaacagaa agaaggaaa agaaggaaa 300 cacaagagaaaacagaa ea	cagatgacca cggtgctcga ccaaaatgtt cacaaccttg ccgtgaccgg cacctttgac	660
capatogiant thictotygo caggogotca cagagacst toaagqiag cgacaaaqto squattiqtaa occocacogg gaacittigst aacatocteg otggatacit tigcacaaaag goo aaggogotta cyacaaag qitggtogti gogacaaatg agaacgacat tottagacagg goo aaggogotta cyacaaagaag cotgcaagoo cogagyaago cgaagoggi 1020 chittiggaaga cygagocgaa aggotcacogag gaggottaga aggagacoot gagcooggog 1080 aaggacatti tiggigotgag caacittigag cgaacactgi gyttictigo caaggagitc 1140 gotgotcacag atggogotaa agacgatca aacaagaago aggotcagoo ggaagitgii 1200 gotgotcacag atggogotaa gygatcocgaa gycticggo cggotcacoo tigaaatcatgi 1260 gacaatggoc gocaggitti tigaagoga gygtigogo aacaccagaa cotcagagiti 1200 gacaatggoc gocaggitti tigaagoga gygtigogo cacaccagac cotcagagii 1320 aacagoggag tytacaaago cacaaagtac gittotyaco cgacactigo cytogogitti 1380 goggggggoo aagaggitcai tigaagoga gygtigogo toaagogaca gaaggagii 1500 gaactatacaa agoaggicai gycagaggaa tittigaco cacaactgo gytitocacci 1440 gocacaccag caagittot tigacagoga tittityagoo tagaaagaag gaaggagii 1500 gaattiacaa agoaggicti gocagaagaa tittigaca tagaaaaga gaaggaggii 1500 gaagactiga agoggogaa ciggcagaag agaagaggaa tigacaagaa gaaggaggii 1500 gaagactiga agogogaa ciggcagaag agaagagaa tigacaagaa gaagagaga 1620 gaagactiga agogogaa ciggcagaag agaagagaa tigacaagaa gaagagaga 1620 gaagactiga agogogaa ciggcagaag agaagagaa tigacaaaaa atgacaagac 1620 gaagactiga agogaaga gacacacaaacaga gyacagaagaagaa gaagagaga 120 gaagagattga agogaaga gaactagaaga gaactagaga gaacacagaga 120 gagaagatga cacaaaacaga gaactagaa gaactagaaga gaacacaagaa 120 gagaagagaga gaacaagaa tigagaaaaga gactagaaaaaa atgacaagac 120 gagaagagaa cacaacaacaacaacaacaacaacaacaacaacaaca	gattgccaag atatcgtcaa ggccatgttc aacgacccag attcgaatgc gacactgaag	720
agosttysta accecacag gaacttegs acatecteg etgataatt tyacacaaaag 900 atgggettys otgtogacaa gttygtogtt gogacaaatg agaacgacat tottgacagg 960 atttggaaag ogggecgeta ogaaaagaag otgcaagac cogaggaage ogcaggeggt 1020 atgcotaaag atgggtaaa ggotcacagag gagggetgaa agagaaccet gagcooggcg 1080 atggacattt tygtytogag caactttgag ogaacactyt gyttottyc caaggagttc 1140 gotgotacag otggectcaa tyacgagttc aacaagaaga aagooggca ggaagttgtg 1200 goatggtaca agtooctaa tyacgagttc aacaagaaga aagooggca ggaagttgtg 1200 gaacatggco gocaggtott tyaaagogga gocgtgageg acaccagac octogagatg 1320 ahogoggaga tytacaaaga cacaaagtac gttetogace ogcactotge ogtogatgt 1380 gaggggggca agaggtoat gtogaggge tocaacga gocgacaccg gutgtocaccg 1440 goccaccag coaagttott tygoagggac tocaacgtoc ogcactotge ogtogatgtt 1380 gogaggggca agaggtoat gtogagggac totgaaggaca gaaccaagac gaacttacaa agoaggtoot gocagaggac ttytytygoo taagagaca gaaggagto 1500 gaactttacaa agoaggtoot gocagaggac ttytytygoo taagagaca gaaggagto 1500 gagaacttga aggotgaaag tygoaggaa gtgagggaa tygtoaagaa gaagaagta 1600 gaagacttga aggotgaaag tagtocataa 1650 2210- SEQ IN NO 2 2210- SE	cttggtgctg tcaactcgat caactggtcc aggatattgg cccagattgt ttactacttc	780
stygottyg ctytogacaa gtggtgyt gogacaasty agaacqacat tottyacagg 950 titttygaaga gyggcgtaa ogaaaagaag cotgcaagc cogaggaagc cycaggggt 1020 stycotcaag atggcytaa ggacaacyag gagggtga aggagacct gagccogyc 1080 atggacatt tygtytogag caacttyag cyaacacyg gyttottyc caaggagtt 1140 gotgotacag ctygoctcaa tgacgaytt acaaagaagc aagcogyca gyaagttyt 1200 goatagtaca agtocotcaa gyctaccyga gycttoggt cygtocacc tgaaatcaty 1260 gacaatggc gocaggtott tgaaagcgag cycgggagg acacccagac cotcagaatg 1320 atcgcggaga tytacaaagc cacaaagtac gttotogacc cyaactctg cytogagt 1380 goggggggcaa agagytcaat gtcgagggc tecaacytec cyaactcgc gtcgytyt 1380 gogcacaccag caaagtctc tygggggc tecaacytec cyaactcgc gtcgytyt 1380 gogcacaccag caaagtctc tygggggc tecaacytec cyaacatcgc getytocacg 1440 goccaccacag caaagtctc tygggcgct tyggcttycg teaaggaca gaaggagtt 1500 gacttacaa agcaggtot gocagagga tytytygac tagaagaag gyaaaagagg 1560 gytyactgag tyggcacaa cyagcagaa gygagggga tttgtaagaa gaaggcgga 1620 gagagactya aggcggaaa cyagcagaaa gygagggga ttgtcaagaa gaaggcgga 1620 gaagactya aggcggaaa taggcagaa gygagaga gyaaaagaa gaaggcaga 1650 **210 SEQ ID NO 2 **211 Linctit 2082 **2213 Linctit 2082 **2214 Linctit 2082 **2215 Linctit 2082 **2215 Linctit 2082 **2215 Linctit 2082 **2216 Linctit 2082 **2217 Linctit 2082 **2217 Linctit 2082 **2218 Linctit 2082 **2218 Linctit 2082 **2218 Linctit 2082 **2219 Lin	cactegtact tttetetgge cagggegtea ceagagaegt teaaggtegg egacaaagte	840
tttggaaga cgggccgcta cgaaaagaag ctgcaagc ccgaggaagc cgcaggcggt 1020 ttgctctaag atggcgtaaa ggctacqag gagggctga aggagacct gagccgggg 1080 atggacattt tggtgtcag caactttgag cgaacactgt ggtttcttgc caaggagtc 1140 gctgctacqg ctggcccaa tgacggag cgactgga caacacgg gagagtcga 1200 gcatggtaca agtccctcaa ggctaccgga ggcttcggtc cggtccaccc tgaaatcatg 1260 gacaatggcc gccaggtctt tgaaaggag cgcgtgagcg acacccagac cctcgagatg 1320 atcgcggaga tgtacaaagc cacaaagtac gttctcgac cgcactctgc cgtcggtgt 1380 gccgacaccag ccaagtctc tgaagggcc tccaacgtcc cgcacatcgc gctgtccacc 1440 gcccacccag ccaagtctc tggggggcc tccaacgtcc cgcacatcgc gctgtccacg 1440 gcccacccag ccaagtctc tgggcggtg tgagcttggc tcaaaggaca gagaagagg 1560 gactttacaa agcaggtcct gccagagaga tttgtgga tagcagagaa ggaaaagag 1560 gcgacttgaa ggccgaaag taggcagaa gtgaagggaga ttgtcaagaa gcaggtcga 1620 gaagacttga aggctgaaag tagtgcataa 1650 **210** SEQ ID NO 2** *2211** LENCTH: 2082 *2211** TTP: DNA **2212** CANAILSH: Hagnaporthe grisea **400** SEQUENCE: 2 **tacgctgtca aataggcgat ggcagattac ctattttgta ttgacaaaaa atgacaagac 60 **cagctgtatc cactgatac gataaggtt tttattactg gccgatgtg ggagacgcg 120 **ggcgaaggtgg gcgaaattga ctaacactga ttttgatg tgcgactgat gcgaagagcc 120 **ggcgaaggtgg gcgaaattga ctaacactga ttttgatga tgcgactgat gcgaagagcc 120 **ggcgaaggtgg gcgaaattga ctaacactga tgttgcaacc aacggggggt cggaagagcc 300 **ggcactctcct tcacagaca tggagaacgg tgctgcaacc aacgggggct cggaagagcc 300 **ggcactctcct tcacagact tgcggaaga ctggcggaagac gattatgggc tctcattcga 360 **gaaccgtcgc aactcgacga ttgggaaaga ctggcgggaa gactcagg cgctgcaagga 360 **gaaccgtcgtc ctcaaaggtc ttgcggctga cggggggac gattatgggc tccatcgaagt 480 **tctcaagcttg tacatctccc cgccgaaga ggctgtgcg ctggtgaagc tgggggaaaa 600 **gcgcgaactcc tgaccttcc gatcaaaga ggttgtgcc ctggtgaagc tgggggaaaa 600 **ccttcaccttgt tgacctctc gstccaaaga ggttgtgcc ctggtgaagc tgggggaca agaagggcaa agaagagaca agaagagaca agaagagaca agaagagaca agaagagaca agaagagaca agaagagaca agaagagaca agaagagaca agaagagacaa agaagagaca agaagagacaaagagaaaaagagaaaaagaagaaaaagagaaaagaag	cgctttgtca cccccaccgg gaactttggt aacatcctgg ctggatactt tgcacaaaag	900
trigecteana atagogtana goeteacaga gagagetqea agagacet gagecogge 1080 atagacattt tygtytoga caactttaga cyaacactty gyttettge caaggagtte 1140 getygetacag etgectean tgacagagte ancaagaage angecygea gyaagtty 1200 geatagytaca agtecetean gyetacegya gyettegyte egytecacee tyaaateaty 1260 gacaatgytean agtecetean gyetacegya gyettegyte egytecacee tyaaateaty 1260 gacaatgytean agtecetean gyetacegya gyettegyte egytecacee tyaaateaty 1320 ategoggaga tytacaaage cacaaagtae gytetegae egeacatege getytecacy 1440 geegaacatte tyaagaggae tecaacgtee egeacatege getytecacy 1440 geegaacaccag canagitete tygggeegit gagettgege teaaggaca gaaggagtte 1500 gacttacaa ageagyteet geegaggae tityttiggae tageaggaa gyaaaagaag 1560 gracetagag tyggeegaa etggeaggaa gigaaggaga tityteaagaa geaggtogag 1620 gagagattya aggeegaaag tagigaagaa gigaaggagaa tityteaagaa geaggeogaa 1620 gaagactiga aggeegaaag tagigaataa 1650 **2210** SEQ ID NO 2 **2211** LENGTH: 2082 **2211** TYPE: DNA **2212** TYPE: DNA **2213** OKANISK: Nagnaporthe grisea **400** SEQUENCE: 2 tacgetytaa aataggegat egaacatiga tyttigeaaca aatggagegeg 120 gegagagtig gegaaatiga etaacactga tittigactga tyegactgat gegacageeg 180 egagacacaac accaacacge agacttyaca gattetgeta etacaaaatee tyeatattia 240 acaagegetge aactegacga tyggagaacgg tyetgeaace aacggggegt eggagaagte 300 geacteteet teacagace accetecaca aaggggagae gattatagge teteattega 360 gaacagetge ceaaagget tyeggeaaa accagaggega gattatagge teteattega 360 gaaccettete teacagace teggagaaga cetgeogaaga gacttagge teteattega 360 gaccetteteet teacagace tyggagaaga cetgeogaaga gacttagge teteattega 360 gaccetteteet teacagace accetecaca accepecaaga gaccegagaa gacttagge teteattega 360 gaccetteteet teacaagee tyggagaaga cetgeogaaga gacttagge teetattega 360 gaccetteacett teacacaaga getggaaga gacttagge tygagacaaa 600 eetteacettg tygagatat teeaaggae etgeagaaga gacttagge tygagagacaa 600 eetteacettg tygagatat teacaagag gyttyteeg etgytgaaga aggaggaa aggaggaaa	atgggcttgc ctgtcgacaa gttggtcgtt gcgacaaatg agaacgacat tcttgacagg	960
atgacattt tggtgtcgag caactttgag cgaacattg ggttcttgc caaggagttc gctgctacgg ctggcctcaa tgacggttc aaraagaag aagccggca ggaagttgtg gcataggtaca agtccctcaa ggctaccgga ggcttcggtc cggtccaccc tgaaatcatg gcataggtaca agtccctcaa ggctaccgga ggcttcggc cggtccaccc tgaaatcatg gacaatggca gcaaggtctt tgaaagcgag cgcgtgagcg acaccagac cctcgagatg aaccgcggag tgtacaaagc cacaaagtac gttctcgacc cgcactcgc cgtcgtgtt gcggggggca agaggtcat ggcggcgtt gagcttgcc cgacatcgc gctgtccaccg gcacaccac caagttctc tggcgccgtt gagcttgcc caaggacca gaaaggaggtc gcacaccaa acaaggtcct tggcgccgtt gagcttgcc caaggaca ggaaaagagg ggagattgaaag tggccggaa ctggcaggaa gtgagggag ttgtcaaga ggaaaagagg gaagacttga aggctgaaag tagtgcataa 2210- SeG ID NO 2 2211- INDEN DNA 2212- TYPE: DNA 2213- INDEN NA 2213- GROANISH: Magnaporthe grisea 4400- SEQUENCE: 2 tacgctgtca aataggcgt ggccgattac ctattttgta ttgacaaaaa atgacaagac 400- SEQUENCE: 2 tacgctgtca cactgatatc gataaggtt ttttattactg gccgttgtg ggagacgcg ggcgagagtg gcgaaattga ctaacactg ttttgactga tgcgattgg ggagacgcg 120 ggcgagagtg gcgaaattga ctaacactg attttgactga tgcgattgg ggagacgcg 120 ggcgagagtg aactcgacga tggagaacgg tgctgcaacc aacggggt cggagaagtc 300 gcactctcct tcacagacct acctcccac aaggggagac gattatggc tctcattcga 360 gaccgtcgtc ctoaaaggct ttgcggcga gcgggggac gaggaggc cggagaagtc 420 cgcggcaacc gagtggaaag ctgcgcagaa gacttaggc cgcgagaagtc 420 cgcggcaacc gagtggaaag ctgcgcagaa gacttaggc cgcgagaaggc 420 cgcggcaacc gagtggaaag ctgcgcagaa gacttaggc cgcaggagac 420 cgcggcaacc gagtggaaag ctgcgcagaa gactcaaggc cgcacagga 420 cgcggcaaccac gagtggaaag ctgcgcagaa gactcaagga cgcgcaggaa 420 cgcggcaaccac gagtggaaag ctgcgcagaa gacctaaggc cgcgcaggaa 420 cgcggcaaccac gagtggaaag ctgccacagaa gacctaaggc cgcgagaagac 420 cgcggcacacc gagtggaaat tcaacactc gagtggaacg ctgcgcagaa 420 cgcgacgactac tcacactcc gaccacagaa ggttgtgcc ctgtgaagac 420 ccctcacacttc tggagctat tcacacgcc caccacactg ttcaaggac gagaggcac 720 aagacaggcac aacactcactt tggtcgcca aacaagtggt gacacggtt cggcgccac 720	ttttggaaga cgggccgcta cgaaaagaag cctgcaagcc ccgaggaagc cgcaggcggt	1020
gretgetacag ctggcetcaa tgacgggte aacaagagc aagacggcca ggaagttgg 1200 gratggtaca agtccetcaa ggctaccgga ggetteggte cggtccacce tgaaatcatg 1260 gratggtaca agtccetcaa ggctaccgga ggetteggte cggtccacce tgaaatcatg 1320 atcgcggggcca gcaaggtcat tgaaagcgag cgcgtgagcg acaccagac cctcgagatg 1320 atcgcggggcca agaggtcaat gtcgaagggcc tccaacgtc cgcacatcgc cgtgtgtcaccg 1440 grcgaggggcca agaggtcat tggggccgtt gagcttgcg tcaaggaca gaaggaggtc 1500 grcaccaccag ccaagtcct tgggcgcgtt gagcttgcg tcaaggaca gaaggaggtc 1500 gracttacaa agcaggtcct gccagaggac tttgttggac tagcagagaa ggaaaagagg 1560 gracttacaa agcaggtcat gccagaggaa gtgagggaga ttgtcaagaa ggaaaagagg 1620 gragacttga aggctgaaag tagtgcagaa gtgaggggag ttgtcaaga aggaggtcga 1620 gragagacttga aggctgaaag tagtgcataa 1650 2210- SEQ ID NO 2 2212- ITTFE: DNA 2213- IRNGTH: 2022 2212- ITTFE: DNA 2213- CACANICHN: Magnaporthe grisea 4400- SEQUENCE: 2 tacgctgtca aataggcgat ggccgattac ctattttgta ttgacaaaaa atgacaagac 60 ggcgagggggg gcgaaattga ctaacactga ttttgactga tgcgatgtg ggagacgcgg 120 ggcggaggtgg gcgaaattga ctaacactga ttttgactga tgcgatgtg ggagacgcgg 180 ggcggaggtgg gcgaaattga ctaacactga ttttgactga tgcgatgtg ggagagggg 220 ggcggcacac cccaacacgc agcttgaca gattctgcta ctacaaatcc tgcatattta 240 acagcgctgta aactcgacga tggggaaagg tgcgtgaaga gattatggc tctcattcga 360 gaccgtcgtc ctcaacaggct ttgcggcga gggggggtct ttcctcatcga 360 gaccgtcgtc ctcaacaggct ttgcggcga gggggggg agactcac gggaggtgc 2420 gaccgtcgtc ctcaacaggct ttgcggcga gcggcggaa gacctcaggg gcgcaggaa 360 gaccgtcgtc ctcaacaggct ttgcggcga gcggcggaa gacctcaggg gcgctgtcga 540 gcgcggcacac gagtggcaa gctgccaca accagaggg ctgctgcaga 360 acctcacctt ctgaacatcc gaccaagga ggttgtgccg ctgtgaagac tggaggacaa 600 acctcacctt ctgaacatct tcaacggcc cagcacagaa aacaagggaa agagaggca 720 aagagaaggcac cacctcactg tggtgcgcg aacaagtggt gaaccggtt cggcgcgcac 770	ctgcctcaag atggcgtaaa ggctcacgag gagggctgca aggagaccct gagcccggcg	1080
gacataggaca agteceteaa ggetacegga ggetteggte eggtecacce tgaaateatg 1260 gacataggaca gecaggtett tgaaagega egegtgageg acacceagac ectegagatg 1320 ategeggaga tgtacaaage cacaaagtac gttetegace egeactetge egtegeacg 1380 geegggggeca agaggteaat gtegagggee tecaacgtee egeacatege egtegecacg 1440 geecacceag coaagteet tggegeegtt gagettgege teaaggaca gaaggagte 1500 gacttacaa ageaggteet geeggaggac ttgttgace tageaggaa gagaaaagag 1560 gigacttgaag tggeeggaa etggeaggaa gtgaggaga ttgtcaagaa geaggtegag 1620 gagaagacttga aggetgaaag tagtgeataa 1650 2210	atggacattt tggtgtcgag caactttgag cgaacactgt ggtttcttgc caaggagttc	1140
accastgoc gocaggtott tgaaagoga ogogtgagog acacccagac cotogagatg 1320 atogoggaga tgtacaaago cacaaagtac gttotogaco ogoactotgo ogtgotgagog 1380 goggaggoca agaggtoaa gtogaggago tocaacgtoo ogoacatogo gotgtocacog gocacccag ccaagttoto tggogocgtt gagottgogo tocaaggaca gaaggagto 1500 gocacccag ccaagttoto tggogocgtt gagottgogo tocaaggaca gagagagag 1560 gogagagagag tggocgagaa ctggoaggaa gtgaggagaa ttgtcaagaa gagaaaagag 1560 gogagagattga aggotgaaa ttggoaggaa gtgaggagaa ttgtcaagaa gagagatoga 1620 gagaagattga aggotgaaag tagtgoataa 1650 **210	gctgctacgg ctggcctcaa tgacgagttc aacaagaagc aagccggcca ggaagttgtg	1200
attectgggag tytacaaagc cacaaagtac gttetegacc egeactetgc egteggtytt 1380 geggggggca agaaggteat gteggaggge tecaacgtec egeacategg egtgtecacg 1440 geccacccag ceaagttete tyggegegtt gagettgege teaaggacca gaaggagtte 1500 gactttacaa ageaggteet gecagaggac tttgttggac tageagagaa ggaaaagagg 1560 gradettacaa ageaggteet gecagaggaa gtgagggaga ttgteaagaa geaggtegag 1620 gaagacttga aggetgaaag tagtgcataa 1650 **2210> SEQ ID NO 2 **2211> LENOTH: 2082 **2211> LENOTH: 2082 **2212> TYPE: DNA **2210> SEQUENCE: 2 **taeggetgtaa caataggegat ggeegattac etattttgta ttgacaaaaa atgacaagac 60 eeggegaggtgg gegaaattga etaacactga ttttgactga tgegactgat ggagageegg 120 ggegaggtgg gegaaattga etaacactga ttttgactga tgegactgat ggacageegg 180 eeggegacaaca cecaacacgc agacttgaca gattetgeta etacaaatce tgeatattta 240 acageggetga aactegacga tggagaacgg tgetgeaace aacggggegt eggagaagtc 300 gecacteteet teacagacet acctetecac aaggggagac gattatggg teteattega 360 gaccegtegte eteaaaggte ttgeggetga egggggtett tteetgeeg aggaagtgc 420 eeggggaace gagtggeaaa getggaaaag cetgeectac accqagettg eegteagagt 480 teteagettg tacateteec eegeegaggt geegacggaa gacctcagg egetegtega 600 eetteacettg tacateteec egeegaggt geggaggaa gacctcagg eggaggacaa 600 eetteacettg tacateteec gatecaagga ggttgtgeec etgatgaag tggaggacaa 600 eetteacettg tacateteec gatecaagga ggttgtgeec etgatgaagt eggaggacaa 600 eetteacettg tagaggatat tecacggeec cagetacteg tteaaggact eggeggecaa 720 aagacaggaca cacctecattg tggteggeec aacaaagtggt gataccggtt eggegecaca 780	gcatggtaca agtccctcaa ggctaccgga ggcttcggtc cggtccaccc tgaaatcatg	1260
gegggggca agaggtcaat gtegagggc tecaacgtee egeacatege getgtecaeg 1440 geccaccag ceaagttete tggegeegt gagettgege teaaggacca gaaggagtte 1500 gactttacaa ageaggteet gecagaggae tttgttggae tageagagaa ggaaaagagg 1560 gtgactgagg tggeegegaa etggeaggaa gtgagggaga ttgteaagaa geaggtegag 1620 gaagacttga aggetgaaag tagtgeataa 1650 **2210> SEQ ID NO 2 **2211> LENOTH: 2082 **2211> LENOTH: 2082 **2212> TYPE: DNA **2213> ORGANISH: Magnaporthe grisea **400> SEQUENCE: 2 **bacgetgtea aataggegat ggeegattae etattttgta ttgacaaaaa atgacaagac 60 cagetgtate cactgatate gataaggtt tttattactg geegatgeeg ggagacgegg 120 ggeggaggtgg gegaaattga etaacactga ttttgactga tgegactgat gegacageeg 180 cagetgtate cactgatate agtacagat ggtetgeaac aacgggget eggagaagte 300 gegeacacaa eccaacacge agacttgaca gattetgeta etacaaatee tgeatattta 240 acaaggegte aactegaega tggagaaag gtetgeaace aacgggget eggagaagte 300 geacteteet teacagacet acctetecac aaggggagee gattatggg teteattega 360 gaccgtegte etcaaaaggte ttgeggetga egggggtett tteetgeeg aggaagtge 420 cgegggeaace gagtggeaaa getggaaaga ectgeectae accgacttg eegteaaggt 480 teteaagettg tacatetee eegeegaggt geegacggaa gacctcagg egetegtega 540 gegegagtate tegacettee gatecaagga ggttgtgee etggtgaage tggaggacaa 600 cetteaacett etgagagtat tecaaggee cagetacteg tteaaggact geggegetae 660 atteettggt aacetettee gatecaagga ggttgtgee etggtgaag agaagggcaa 720 aagacaggaca caccteactg tggteggee aacaagtggt gataceggtt eggeggecat 780	gacaatggcc gccaggtctt tgaaagcgag cgcgtgagcg acacccagac cctcgagatg	1320
gaccacaccag ccaagtctct tygegecegtt gagettgege teaaggaca gaaggagtte 1500 gactttacaa agcaggtect gecagaggae tttgttggae tageaggaa ggaaaaggag 1560 gtgactgagg tygeegegaa etggeaggaa gtgagggaga ttgteaagaa geaggtegag 1620 gaagacttga aggetgaaag tagtgeataa 1650 <pre> <210</pre>	atogoggaga tgtacaaagc cacaaagtac gttotogacc cgcactotgc cgtcggtgtt	1380
gactttacaa agcaggtcct gccagaggac tttgttggac tagcagagaa ggaaaagagg 1560 gtgactgagg tggccgcgaa ctggcaggaa gtgagggaga ttgtcaagaa gcaggtcgag 1620 gaagacttga aggctgaaag tagtgcataa 1650 <pre> <210</pre>	gcgggggcca agaggtcaat gtcgagggcc tccaacgtcc cgcacatcgc gctgtccacg	1440
gragactgag tggccgcgaa ctggcaggaa gtgagggaga ttgtcaagaa gcaggtcgag 1620 gaagacttga aggctgaaag tagtgcataa 1650 <pre> <210</pre>	gcccacccag ccaagttctc tggcgccgtt gagcttgcgc tcaaggacca gaaggagttc	1500
gaagacttga aggctgaaag tagtgcataa 1650 2210> SEQ ID NO 2 2211> LENGTH: 2082 2212> TYPE: DNA 2213> ORGANISM: Magnaporthe grisea 2400> SEQUENCE: 2 tacgctgtca aataggcgat ggccgattac ctattttgta ttgacaaaaa atgacaagac 60 cagctgtatc cactgatatc gataaggtt tttattactg gccgatgcg ggagacgcgg 120 ggcgagagtgg gcgaaattga ctaacactga ttttgactga tgcgactgat gcgacagccg 180 cgcgacaacac cccaacacgc agacttgaca gattctgcta ctacaaatcc tgcatattta 240 acagcgtgtc aactcgacga tggagaacgg tgctgcaacc aacggggcgt cggagaagtc 300 gcactctcct tcacagacct acctctccac aagggggac gattatgggc tctcattcga 360 gaccgtcgtc ctcaaaggtc ttgcggctga cgggggtctt ttcctgcccg aggaagtgcc 420 cgcggcaacc gagtggcaaa gctggaaaga cctgccctac accgagcttg ccgtcaaggt 480 tctcagcttg tacatctccc ccgccgagt gccgacggaa gacctcaggg cgctcgtcga 540 gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcaccttg ctggagctat tccacggccc cagctactcg ttcaaggact gcgcgctgca 660 attccttggt aacctcttcg agtacttttt gactcgcaag aacaagggaa aggagggcaa 720 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgccat 780	gactttacaa agcaggtcct gccagaggac tttgttggac tagcagagaa ggaaaagagg	1560
<pre><210> SEQ ID NO 2 <2211> LENGTH: 2082 <2212> Type: DNA <2213> ORGANISM: Magnaporthe grisea </pre> <pre><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><adobese="2"><</adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></adobese="2"></pre>	gtgactgagg tggccgcgaa ctggcaggaa gtgagggaga ttgtcaagaa gcaggtcgag	1620
<pre> c211> LENGTH: 2082 c212> TYPE: DNA c213> ORGANISM: Magnaporthe grisea c400> SEQUENCE: 2 tacgctgtca aataggcgat ggccgattac ctattttgta ttgacaaaaa atgacaagac 60 cagctgtatc cactgatatc gataaggttt tttattactg gccgattgcg ggagacgcgg 120 ggcgaggtgg gcgaaattga ctaacactga ttttgactga tgcgactgat gcgacagccg 180 cagcgacaaca cccaacacgc agacttgaca gattctgcta ctacaaatcc tgcatattta 240 acagcgctgc aactcgacga tggagaacgg tgctgcaacc aacggggggt cggagaagtc 300 gcactctcct tcacagacct acctctccac aaggggagac gattatggc tctcattcga 360 gaccgtcgtc ctcaaaagtc ttgcggctga cgggggtctt ttcctgcccg aggaagtgc 420 cgcggcaacc gagtggcaaa gctggaaaga cctgccctac accgagcttg ccgtcaaggt 480 tctcagcttg tacatctccc ccgccgaggt gccgacggaa gacctcaggg cgctcgtcga 540 gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcacctg ctggagctat tccacggcc cagctactcg ttcaaggact gcgcgctgca 660 attccttggt aacctcttcg agtactttt gactcgcaag aacaagggaa aggagggcaa 720 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgccat 780 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgccat 780 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgccat 780 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgcccat 780 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgccat 780 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcggccat 780 agacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcgccat 780 agacagcaccactcactg tggtcgcgcaccaccactcg tcaccactcgcgcc cacctcactg tggcgccaccaccactcactg tggcgccaccaccaccaccaccaccaccaccaccaccacca</pre>	gaagacttga aggctgaaag tagtgcataa	1650
tacgctytca aataggcgat ggccgattac ctattttyta ttgacaaaaa atgacaagac 60 cagctytatc cactgatatc gataaggttt tttattactg gccgatytcg ggagacgcgg 120 ggcgaggtgg gcgaaattga ctaacactga ttttgactga tgcgactgat gcgacagccg 180 cgcgacaacac cccaacacgc agacttgaca gattctgcta ctacaaatcc tgcatattta 240 acagcgctgc aactcgacga tggagaacgg tgctgcaacc aacggggcgt cggagaagtc 300 gcactctcct tcacagacct acctctccac aaggggagac gattatgggc tctcattcga 360 gaccgtcgtc ctcaaaggtc ttgcggctga cgggggtctt ttcctgcccg aggaagtgcc 420 cgcgggcaacc gagtggcaaa gctggaaaga cctgccctac accgagcttg ccgtcaaggt 480 tctcagcttg tacatctccc ccgccgaggt gccgacggaa gacctcaggg cgctcgtcga 540 gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcacctg ctggagctat tccacggccc cagctactcg ttcaaggact gcgcgctgca 660 attccttggt aacctcttcg agtactttt gactcgcaag aacaagggaa aggagggcaa 720 aagacaggcac cacctcactg tggtcggcg aacaagtggt gataccggtt cggcggccat 780	<210> SEQ ID NO 2 <211> LENGTH: 2082 <212> TYPE: DNA <213> ORGANISM: Magnaporthe grisea	
cagetgtate cactgatate gataaggttt tttattactg geogatgteg ggagaegegg 120 ggegaggtgg gegaaattga etaacactga ttttgactga tgegactgat gegacageeg 180 egegacaaca cecaacacge agacttgaca gattetgeta etacaaatee tgeatattta 240 acagegetge aactegacga tggagaaegg tgetgeaace aacggggegt eggagaagte 300 geacteteet teacagacet acetetecac aaggggagae gattatggge teteattega 360 gacegtegte eteaaaggte ttgeggetga egggggtett tteetgeeeg aggaagtgee 420 egeggeaace gagtggeaaa getggaaaga eetgeeetac acegagettg eegteaaggt 480 eteteagettg tacateteee eegeegaggt geegaeggaa gaceteaggg egetegtega 540 gegegagetac tegacettee gateeaagga ggttgtgeeg etggtgaage tggaggacaa 600 eetteacetg etggagetat teeaeggeee eagetacteg tteaaggaet gegegetgea 660 atteettggt aacetetteg agtactttt gactegeaag aacaagggaa aggagggeaa 720 aagacaggeae caceteactg tggteggeg aacaagtggt gataceggtt eggeggecat 780	<400> SEQUENCE: 2	
ggegaggtgg gegaaattga etaacactga ttttgactga tgegactgat gegacageeg 180 egegacaaca cecaacacge agacttgaca gattetgeta etacaaatee tgeatattta 240 acagegetge aactegacga tggagaacgg tgetgeaace aacggggegt eggagaagte 300 gcacteteet teacagacet aceteteeac aaggggagac gattatggge teteattega 360 gacegtegte eteaaaggte ttgeggetga egggggtett tteetgeeg aggaagtgee 420 egegggeaace gagtggeaaa getggaaaga eetgeeetac acegagettg eegteaaggt 480 teeteagettg tacateteee eegeegaggt geegacggaa gaceteaggg egetegtega 540 gegegagetace tegacettee gateeaagga ggttgtgeeg etggtgaage tggaggacaa 600 eetteacetg etggagetat teeacggeee eagetacteg tteaaggaet gegegetgea 660 atteettggt aacetetteg agtaetttt gactegeaag aacaagggaa aggagggeaa 720 aagacaggeac caceteactg tggteggeg aacaagtggt gataceggtt eggeggeeat 780	tacgctgtca aataggcgat ggccgattac ctattttgta ttgacaaaaa atgacaagac	60
egegacaaca cccaacacge agacttgaca gattetgeta ctacaaatec tgcatattta 240 acaagegetge aactegacga tggagaacgg tgetgeaace aacggggegt eggagaagte 300 geacteteet teacagacet acetetecac aaggggagac gattatggge teteattega 360 gacegtegte eteaaaggte ttgeggetga egggggtett tteetgeeg aggaagtgee 420 eggeggeaace gagtggeaaa getggaaaga cetgeeetac acegagettg eegteaaggt 480 teteagettg tacateteee eegeegaggt geegaeggaa gaceteaggg egetegtega 540 gegegagetac tegacettee gateeaagga ggttgtgeeg etggtgaage tggaggacaa 600 eetteacetg etggagetat teeaeggeee eagetacteg tteaaggact gegegetgea 660 atteettggt aacetetteg agtactttt gactegeaag aacaagggaa aggagggeaa 720 aagacaggeac caceteactg tggteggege aacaagtggt gataceggtt eggeggeeat 780	cagctgtatc cactgatatc gataaggttt tttattactg gccgatgtcg ggagacgcgg	120
acagegetge aactegacga tggagaacgg tgetgeaace aacggggegt eggagaagte 300 geacteteet teacagacet aceteteeae aaggggagac gattatggge teteattega 360 gacegtegte eteaaaggte ttgeggetga egggggtett tteetgeeeg aggaagtgee 420 eggeggeaace gagtggeaaa getggaaaga eetgeeetae acegagettg eegteaaggt 480 teteagettg tacateteee eegeegaggt geegaeggaa gaceteaggg egetegtega 540 gegegagetae tegacettee gateeaagga ggttgtgeeg etggtgaage tggaggacaa 600 eetteacetg etggagetat tecaeggeee eagetaeteg tteaaggaet gegegetgea 660 atteettggt aacetetteg agtaetttt gactegeaag aacaagggaa aggagggeaa 720 aagacaggeae eaceteactg tggteggege aacaagtggt gataeeggtt eggeggeeat 780	ggcgaggtgg gcgaaattga ctaacactga ttttgactga tgcgactgat gcgacagccg	180
gcactctcct tcacagacct acctctccac aaggggagac gattatgggc tctcattcga 360 gaccgtcgtc ctcaaaggtc ttgcggctga cgggggtctt ttcctgcccg aggaagtgcc 420 cgcgggcaacc gagtggcaaa gctggaaaga cctgccctac accgagcttg ccgtcaaggt 480 tctcagcttg tacatctccc ccgccgaggt gccgacggaa gacctcaggg cgctcgtcga 540 gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcacctg ctggagctat tccacggccc cagctactcg ttcaaggact gcggcgctgca 660 attccttggt aacctcttcg agtactttt gactcgcaag aacaagggaa aggagggcaa 720 agacaggcac cacctcactg tggtcggcgc aacaagtggt gataccggtt cggcggccat 780	cgcgacaaca cccaacacgc agacttgaca gattctgcta ctacaaatcc tgcatattta	240
gaccgtcgtc ctcaaaggtc ttgcggctga cgggggtctt ttcctgcccg aggaagtgcc 420 cgcgggcaacc gagtggcaaa gctggaaaga cctgccctac accgagcttg ccgtcaaggt 480 tctcagcttg tacatctccc ccgccgaggt gccgacggaa gacctcaggg cgctcgtcga 540 gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcacctg ctggagctat tccacggccc cagctactcg ttcaaggact gcgcgctgca 660 attccttggt aacctcttcg agtactttt gactcgcaag aacaagggaa aggagggcaa 720 agacaggcac cacctcactg tggtcggcgc aacaagtggt gataccggtt cggcggccat 780	acagcgctgc aactcgacga tggagaacgg tgctgcaacc aacggggcgt cggagaagtc	300
egegggaacc gagtggcaaa getggaaaga cetgecetac acegagettg cegteaaggt 480 teteagettg tacateteec eegeegaggt geegaeggaa gaceteaggg egetegtega 540 gegcagetac tegacettee gatecaagga ggttgtgeeg etggtgaage tggaggacaa 600 eetteacetg etggagetat tecaeggeec eagetacteg tteaaggact gegegetgea 660 atteettggt aacetetteg agtactttt gactegeaag aacaagggaa aggagggeaa 720 agacaggeac caceteactg tggteggege aacaagtggt gataceggtt eggeggeeat 780	gcacteteet teacagacet aceteteeac aaggggagae gattatggge teteattega	360
tetecagetty tacatetece eegeegaggt geegaeggaa gaceteaggg egetegtega 540 gegeagetac tegacettee gatecaagga ggttgtgeeg etggtgaage tggaggacaa 600 cetteacetg etggagetat tecaeggeee eagetacteg tteaaggact gegegetgea 660 atteettggt aacetetteg agtactttt gactegeaag aacaagggaa aggagggeaa 720 agacaggeae eaceteactg tggteggege aacaagtggt gataceggtt eggeggeeat 780	gaccgtcgtc ctcaaaggtc ttgcggctga cgggggtctt ttcctgcccg aggaagtgcc	420
gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcacctg ctggagctat tccacggccc cagctactcg ttcaaggact gcgcgctgca 660 attccttggt aacctcttcg agtacttttt gactcgcaag aacaagggaa aggagggcaa 720 agacaggcac cacctcactg tggtcggcgc aacaagtggt gataccggtt cggcggccat 780	cgcggcaacc gagtggcaaa gctggaaaga cctgccctac accgagcttg ccgtcaaggt	480
gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa 600 ccttcacctg ctggagctat tccacggccc cagctactcg ttcaaggact gcgcgctgca 660 attccttggt aacctcttcg agtacttttt gactcgcaag aacaagggaa aggagggcaa 720 agacaggcac cacctcactg tggtcggcgc aacaagtggt gataccggtt cggcggccat 780	tctcagcttg tacatctccc ccgccgaggt gccgacggaa gacctcaggg cgctcgtcga	540
attecttggt aacetetteg agtaettttt gaetegeaag aacaagggaa aggagggeaa 720 agaeaggeae caceteaetg tggteggege aacaagtggt gataeeggtt eggeggeeat 780	gcgcagctac tcgaccttcc gatccaagga ggttgtgccg ctggtgaagc tggaggacaa	600
attecttggt aacetetteg agtaetttt gaetegeaag aacaagggaa aggagggeaa 720 agaeaggeae caceteaetg tggteggege aacaagtggt gataeeggtt eggeggeeat 780	ccttcacctg ctggagctat tccacggccc cagctactcg ttcaaggact gcgcgctgca	660
agacaggcac cacctcactg tggtcggcgc aacaagtggt gataccggtt cggcggccat 780	attccttggt aacctcttcg agtacttttt gactcgcaag aacaagggaa aggagggcaa	720
ctatggtctt cgcaacaaga aggatgtttc cgtcttcatc ctgcacccca agggtcgtgt 840	agacaggcac cacctcactg tggtcggcgc aacaagtggt gataccggtt cggcggccat	780
	ctatggtctt cgcaacaaga aggatgtttc cgtcttcatc ctgcacccca agggtcgtgt	840

aagccccatc caggaggccc agatgaccac ggtgctcgac caaaatgttc acaaccttgc cgtgaccggc acctttgacg attgccaaga tatcgtcaag gccatgttca acgacccaga

-continued

ttcg	gaato	gcg a	acact	tgaaq	gc ti	eggt	gctgt	: caa	actc	gatc	aact	ggto	ca (ggata	attggc	: 1020
ccag	jatto	gtt 1	tacta	actto	cc a	ctcgt	actt	tto	ctcto	ggcc	agg	gegte	ac (caga	gacgtt	1080
caag	gtc	ggc (gaca	aagto	cc go	cttte	gtcac	ccc	ccaco	ggg	aact	ttgg	jta (acato	ctggc	1140
tgga	atact	tt (gcaca	aaaa	ga to	gggct	tgcc	tgt:	cgad	aag	ttg	gtcgt	tg (cgaca	aatga	1200
gaad	gaca	att o	cttga	acag	gt ti	tgga	aagac	gg	gaaga	ctac	gaaa	aagaa	ıgc (ctgca	agccc	1260
cgag	gaag	daa d	gcag	gaggt	to to	gaato	caaga	ı tg	gcgta	aag	gcto	cacga	ıgg i	agggo	ctgcaa	1320
ggag	jacco	ctg a	agcc	cggc	ga to	ggaca	atttt	: ggt	gtc	gagc	aact	ttga	ıgc (gaaca	actgtg	1380
gttt	ctt	gcc a	aagga	agtto	cg ct	gcta	acggo	t t g	gaata	caat	gac	gagtt	ca (acaa	gaagca	1440
agco	ggc	cag o	gaag	ttgt	gg ca	atggt	acaa	gto	ccct	caag	gcta	accgg	gag (gctto	eggtee	1500
ggto	caco	cct (gaaat	tcat	gg a	caato	ggaag	g dda	aggto	ttt	gaaa	agcga	ıgc (gcgt	gagcga	1560
caco	caga	acc o	ctcga	agato	ga to	cgcg	gagat	: gta	acaaa	agcc	acaa	agta	icg .	ttcto	gacco	1620
gcac	ctcto	daa d	gtcg	gtgti	tg c	gggg	gccaa	ı gaç	ggtca	aatg	tcga	agggc	ct (ccaa	gtaca	1680
gcac	catco	geg (ctgto	ccac	gg co	ccaco	ccago	caa	gtto	ctct	ggc	gaagt	tg	agcti	geget	1740
caag	gaco	cag a	aagga	agtto	cg a	cttta	acaaa	ı gca	aggto	cctg	cca	gagga	ct ·	ttgti	ggact	1800
agca	agaga	aag q	gaaa	agag	gg to	gacto	gaggt	ggo	ccgcg	jaac	tgg	cagga	ag ·	tgag	ggagat	1860
tgto	aaga	aag o	caggi	tcga	gg aa	agact	tgaa	a ggo	ctgaa	agt	agto	gcata	at (cacga	agccgg	1920
agtgcagtag aaaatggtgt cgagatcagc atctagattt gctttcctag agatatgcaa 1										1980						
acatttactt attctggacc ctgaatgcag ccccaagggt gcactagatc ggataactgg 2										2040						
aggtttagac gcggccgact tttccggagg tttttgaaag gg										2082						
<210> SEQ ID NO 3 <211> LENGTH: 549 <212> TYPE: PRT <213> ORGANISM: Magnaporthe grisea <400> SEQUENCE: 3																
Met 1	Glu	Asn	Gly	Ala 5	Ala	Thr	Asn	Gly	Ala 10	Ser	Glu	Lys	Ser	His 15	Ser	
Pro	Ser	Gln	Thr 20	Tyr	Leu	Ser	Thr	Arg 25	Gly	Asp	Asp	Tyr	Gly 30	Leu	Ser	
Phe	Glu	Thr	Val	Val	Leu	Lys	Gly 40	Leu	Ala	Ala	Asp	Gly 45	Gly	Leu	Phe	
Leu	Pro 50	Glu	Glu	Val	Pro	Ala 55	Ala	Thr	Glu	Trp	Gln 60	Ser	Trp	Lys	Asp	
Leu 65	Pro	Tyr	Thr	Glu	Leu 70	Ala	Val	Lys	Val	Leu 75	Ser	Leu	Tyr	Ile	Ser 80	
Pro	Ala	Glu	Val	Pro 85	Thr	Glu	Asp	Leu	Arg 90	Ala	Leu	Val	Glu	Arg 95	Ser	
Tyr	Ser	Thr	Phe	Arg	Ser	Lys	Glu	Val	Val	Pro	Leu	Val	L y s 110	Leu	Glu	
λαν			•	_	_	Clu	T.e11	Phe	His	Glv	Pro	Ser	Tvr	Ser	Phe	
чер	Asn	Leu 115	His	Leu	Leu	Giu	120			011		125	_1_			

Thr Arg Lys Asn Lys Gly Lys Glu Gly Lys Asp Arg His His Leu Thr 145 150 155 160

Val Val Gly Ala Thr Ser Gly Asp Thr Gly Ser Ala Ala Ile Tyr Gly 165 $$170\$

-continued

Leu	Arg	Asn	L y s 180	Lys	Asp	Val	Ser	Val 185	Phe	Ile	Leu	His	Pro 190	Lys	Gly
Arg	Val	Ser 195	Pro	Ile	Gln	Glu	Ala 200	Gln	Met	Thr	Thr	Val 205	Leu	Asp	Gln
Asn	Val 210	His	Asn	Leu	Ala	Val 215	Thr	Gly	Thr	Phe	Asp 220	Asp	Cys	Gln	Asp
Ile 225	Val	Lys	Ala	Met	Phe 230	Asn	Asp	Pro	Asp	Ser 235	Asn	Ala	Thr	Leu	Lys 240
Leu	Gly	Ala	Val	Asn 245	Ser	Ile	Asn	Trp	Ser 250	Arg	Ile	Leu	Ala	Gln 255	Ile
Val	Tyr	Tyr	Phe 260	His	Ser	Tyr	Phe	Ser 265	Leu	Ala	Arg	Ala	Ser 270	Pro	Glu
Thr	Phe	L y s 275	Val	Gly	Asp	Lys	Val 280	Arg	Phe	Val	Thr	Pro 285	Thr	Gly	Asn
Phe	Gly 290	Asn	Ile	Leu	Ala	Gly 295	Tyr	Phe	Ala	Gln	Lys 300	Met	Gly	Leu	Pro
Val 305	Asp	Lys	Leu	Val	Val 310	Ala	Thr	Asn	Glu	Asn 315	Asp	Ile	Leu	Asp	Arg 320
Phe	Trp	Lys	Thr	Gly 325	Arg	Tyr	Glu	Lys	L y s 330	Pro	Ala	Ser	Pro	Glu 335	Glu
Ala	Ala	Gly	Gly 340	Leu	Pro	Gln	Asp	Gl y 345	Val	Lys	Ala	His	Glu 350	Glu	Gly
Cys	Lys	Glu 355	Thr	Leu	Ser	Pro	Ala 360	Met	Asp	Ile	Leu	Val 365	Ser	Ser	Asn
Phe	Glu 370	Arg	Thr	Leu	Trp	Phe 375	Leu	Ala	Lys	Glu	Phe 380	Ala	Ala	Thr	Ala
Gly 385	Leu	Asn	Asp	Glu	Phe 390	Asn	Lys	Lys	Gln	Ala 395	Gly	Gln	Glu	Val	Val 400
Ala	Trp	Tyr	Lys	Ser 405	Leu	Lys	Ala	Thr	Gly 410	Gly	Phe	Gly	Pro	Val 415	His
Pro	Glu	Ile	Met 420	Asp	Asn	Gly	Arg	Gln 425	Val	Phe	Glu	Ser	Glu 430	Arg	Val
Ser	Asp	Thr 435	Gln	Thr	Leu	Glu	Met 440	Ile	Ala	Glu	Met	Tyr 445	Lys	Ala	Thr
Lys	Ty r 450	Val	Leu	Asp	Pro	His 455	Ser	Ala	Val	Gly	Val 460	Ala	Gly	Ala	Lys
Arg 465	Ser	Met	Ser	Arg	Ala 470	Ser	Asn	Val	Pro	His 475	Ile	Ala	Leu	Ser	Thr 480
Ala	His	Pro	Ala	L y s 485	Phe	Ser	Gly	Ala	Val 490	Glu	Leu	Ala	Leu	Lys 495	Asp
Gln	Lys	Glu	Phe 500	Asp	Phe	Thr	Lys	Gln 505	Val	Leu	Pro	Glu	Asp 510	Phe	Val
Gly	Leu	Ala 515	Glu	Lys	Glu	Lys	Arg 520	Val	Thr	Glu	Val	Ala 525	Ala	Asn	Trp
Gln	Glu 530	Val	Arg	Glu	Ile	Val 535	Lys	Lys	Gln	Val	Glu 540	Glu	Asp	Leu	Lys
Ala 545	Glu	Ser	Ser	Ala											

What is claimed is:

- 1. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) contacting a fungal Threonine synthase polypeptide with said test compound; and
 - b) detecting the presence or absence of binding between said test compound and said fungal Threonine synthase polypeptide;
 - wherein binding indicates that said test compound is a $_{10}$ candidate for an antibiotic.
- 2. The method of claim 1, wherein said Threonine synthase polypeptide is a Magnaporthe Threonine synthase polypeptide.
- 3. The method of claim 1, wherein said Threonine synthase polypeptide is SEQ ID NO: 3.
- 4. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 1 has antifungal activity, further comprising:
 - contacting a fungus or fungal cells with said antibiotic $_{20}$ candidate and detecting the decrease in growth, viability, or pathogenicity of said fungus or fungal
- 5. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) contacting said test compound with at least one polypeptide selected from the group consisting of: a polypeptide having at least ten consecutive amino acids of a fungal Threonine synthase, a polypeptide having at least 50% sequence identity with a fungal Threonine 30 synthase, and a polypeptide having at least 10% of the activity thereof; and
 - b) detecting the presence and/or absence of binding between said test compound and said polypeptide;
 - wherein binding indicates that said test compound is a 35 candidate for an antibiotic.
- 6. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 5 has antifungal activity, further comprising:
 - contacting a fungus or fungal cells with said antibiotic 40 candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.
- 7. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) contacting O-phospho-L-homoserine and water with a Threonine synthase;
 - b) contacting O-phospho-L-homoserine and water with Threonine synthase and said test compound; and
 - c) determining the change in concentration for at least one 50 of the following: O-phospho-L-homoserine, L-threonine, orthophosphate, and water;
 - wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.
- 8. The method of claim 7, wherein said Threonine synthase is a fungal Threonine synthase.
- 9. The method of claim 7, wherein said Threonine synthase is a Magnaporthe Threonine synthase.
- 10. The method of claim 7, wherein said Threonine 60 synthase is SEQ ID NO: 3.
- 11. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 7 has antifungal activity, further comprising:
 - contacting a fungus or fungal cells with said antibiotic 65 candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

- 12. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) contacting L-threonine and orthophosphate with a Threonine synthase;
- b) contacting L-threonine and orthophosphate with a Threonine synthase and said test compound; and
- c) determining the change in concentration for at least one of the following: O-phospho-L-homoserine, L-threonine, orthophosphate, and water;
- wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.
- 13. The method of claim 12, wherein said Threonine synthase is a fungal Threonine synthase.
 - 14. The method of claim 12, wherein said Threonine synthase is a Magnaporthe Threonine synthase.
 - 15. The method of claim 12, wherein said Threonine synthase is SEQ ID NO: 3.
 - 16. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 12 has antifungal activity, further comprising:
 - contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.
 - 17. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) contacting O-phospho-L-homoserine and water with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with Threonine synthase, a polypeptide having at least 50% sequence identity with a Threonine synthase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a Threonine synthase
 - b) contacting O-phospho-L-homoserine and water with said polypeptide and said test compound; and
 - c) determining the change in concentration for at least one of the following: O-phospho-L-homoserine, L-threonine, orthophosphate, and water;
 - wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.
- 18. A method for identifying a test compound as a ⁴⁵ candidate for an antibiotic, comprising:
 - a) contacting L-threonine and orthophosphate with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a Threonine synthase, a polypeptide having at least 50% sequence identity with a Threonine synthase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a Threonine synthase
 - b) contacting L-threonine and orthophosphate, with said polypeptide and said test compound; and
 - c) determining the change in concentration for at least one of the following: O-phospho-L-homoserine, L-threonine, orthophosphate, and water;
 - wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.
 - 19. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) measuring the expression of a Threonine synthase in a fungal cell, cells, tissue, or organism in the absence of said compound;

34

- b) contacting said fungal cell, cells, tissue, or organism with said test compound and measuring the expression of said Threonine synthase in said fungus or fungal cell;
- c) comparing the expression of Threonine synthase in steps (a) and (b);
- wherein a lower expression in the presence of said test compound indicates that said compound is a candidate for an antibiotic.
- 20. The method of claim 19 wherein said cell, cells, tissue, or organism is, or is derived from a *Magnaporthe* fungus or fungal cell.
- 21. The method of claim 19, wherein said Threonine synthase is SEQ ID NO: 3.
- 22. The method of claim 19, wherein the expression of Threonine synthase is measured by detecting THR4 mRNA.
- 23. The method of claim 19, wherein the expression of Threonine synthase is measured by detecting Threonine synthase polypeptide.
- **24.** A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) providing cells having one form of a Threonine synthase gene, and providing comparison cells having a different form of a Threonine synthase gene,
 - b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound;
 - wherein a difference in growth between said cells and said comparison cells in the presence of said compound 30 indicates that said compound is a candidate for an antibiotic.
- 25. The method of claim 24 wherein the cells are fungal cells.
- 26. The method of claim 24 wherein the cells are Mag- 35 naporthe cells.
- 27. The method of claim 24 wherein said form and said comparison form of the Threonine synthase are fungal Threonine synthases.
- **28**. The method of claim **24**, wherein at least one form is 40 a *Magnaporthe* Threonine synthase.
- 29. The method of claim 24 wherein said form and said comparison form of the Threonine synthase are non-fungal Threonine synthases.
- **30**. The method of claim **24** wherein one form of the 45 Threonine synthase is a fungal Threonine synthase, and the other form is a non-fungal Threonine synthase.
- **31.** A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - a) providing cells having one form of a gene in the ⁵⁰ L-threonine biochemical and/or genetic pathway and providing comparison cells having a different form of said gene.
 - b) contacting said cells and comparison cells with a said test compound,
 - c) determining the growth of said cells and comparison cells in the presence of said test compound;

- wherein a difference in growth between said cells and said comparison cells in the presence of said compound indicates that said compound is a candidate for an antibiotic.
- 32. The method of claim 31 wherein the cells are fungal cells.
- 33. The method of claim 31 wherein the cells are Magnaporthe cells.
- 34. The method of claim 31 wherein said form and said comparison form of the L-threonine biosynthesis gene are fungal L-threonine biosynthesis genes.
- 35. The method of claim 31, wherein at least one form is a *Magnaporthe* L-threonine biosynthesis gene.
- **36**. The method of claim **31** wherein said form and said comparison form of the L-threonine biosynthesis genes are non-fungal L-threonine biosynthesis genes.
- 37. The method of claim 31 wherein one form of the L-threonine biosynthesis gene is a fungal L-threonine biosynthesis gene, and the other form is a non-fungal L-threonine biosynthesis gene.
- 38. A method for determining whether a test compound identified as an antibiotic candidate by the method of claim 31 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.
- **39**. A method for identifying a test compound as a candidate for an antibiotic, comprising:
 - (a) providing paired growth media; comprising a first medium and a second medium, wherein said second medium contains a higher level of L-threonine than said first medium;
 - (b) contacting an organism with said test compound;
 - (c) inoculating said first and second media with said organism; and
 - (d) determining the growth of said organism;
 - wherein a difference in growth of the organism between said first and second media indicates that said test compound is a candidate for an antibiotic.
- 40. The method of claim 39, wherein said organism is a fungus.
- **41**. The method of claim **39**, wherein said organism is *Magnaporthe* .
- **42**. An isolated polynucleotide comprising a nucleotide sequence that encodes a polypeptide of SEQ ID NO: 3.
- **43**. The polynucleotide of claim **42** comprising the nucleotide sequence of SEQ ID NO: 1.
- **44.** An expression cassette comprising the polynucleotide of claim **43**.
- **45**. The isolated polynucleotide of claim **42** comprising a nucleotide sequence of at least 50 to at least 95% sequence identity to SEQ ID NO: 1.
- **46**. An isolated polypeptide consisting essentially of the amino acid sequence of SEQ ID NO: 3.
- **47**. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

* * * * *